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ABSTRACT 
The main goal of this dissertation was to explore the development of a new generation of green 
nanoformulations through the production of biocompatible palladium nanoparticles using 
resveratrol to treat, image and evaluate the efficacy of the formulations in prostate cancer cells 
with minimal toxicity to surrounding normal tissues.  
 
This dissertation is classified into three parts with three main objectives of the producing and 
characterizing resveratrol-derived phenols and polyphenols encapsulated palladium nanoparticles 
(Res-PdNPs) for the imaging and treatment of prostate cancer. Rigorous studies were performed 
for the optimization of the synthesis to achieve increased resveratrol-derived phenols and 
polyphenols corona loading on the palladium nanoparticle surface capable of providing adjuvant 
therapeutic benefits through delivering potent doses of both resveratrol phenols and 
nanoparticles directly to prostate cancer cells. A total of four formulations were produced Res-
PdNP-1 (resveratrol-palladium nanoparticles), Res-PdNP-2 (increased resveratrol corona loaded 
palladium nanoparticles), Res-PdNP-3 (resveratrol-gum arabic stabilized palladium 
nanoparticles) and Res-PdNP-4 (increased resveratrol corona loaded and compacted with gum 
arabic stabilized palladium nanoparticles), respectively. Electron microscopic (TEM) results 
revealed that role of gum arabic was not limited to the stability of the nanoparticles but also 
facilitated the crystallization of the produced palladium nanoparticles (Res-PdNP-3 and Res-
PdNP-4) and subsequently provided a supportive matrix for increased resveratrol phenols 
loading capacity. In vitro evaluation of the Res-PdNPs showed that Res-PdNP-1 and Res-PdNP-
2, were not stable in serum while Res-PdNP-3 and Res-PdNP-4 maintained superior stability, 
thus ruling out further analysis using Res-PdNP-1 and Res-PdNP-2. The LC-MS/MRM results 
xxii 
 
confirmed increased resveratrol phenols loading in Res-PdNP-4 when compared to Res-PdNP-3; 
consequently Res-PdNP-4 nanoparticles were confirmed as the ideal nanoformulation to improve 
the bioavailability, biodistribution and emblematize as an adjuvant therapy to induce selective 
and specific tumor-cell-death.  
 
The prostate tumor selective and specific affinity of Res-PdNP-4 nanoparticles through 
numerous cellular internalization studies undoubtedly revealed that Res-PdNP-4 nanoparticles 
can be internalized into prostate cancer cells via laminin receptor-mediated endocytosis which 
are receptors overexpressed on prostate cancer cells compared to normal cells. The Res-PdNP-4 
nanoparticles were evaluated to investigate in vitro cellular toxicity against both prostate cancer 
(PC-3) cells and normal human aortic endothelial cells (HAEC). Results indicated that Res-
PdNP-4 exhibited comparable anticancer efficacy against prostate cancer cells as 
chemotherapeutic drugs (cisplatin and etoposide). However, the results showed that cisplatin and 
etoposide treatments were highly toxic to normal cells while Res-PdNP-4 nanoparticles 
presented no toxicity further corroborating laminin receptor-mediated delivery, making Res-
PdNP-4 nanoparticles selective and specific to prostate cancer cells.  
 
Res-PdNP-4 nanoparticles were investigated in vivo using a human prostate tumor-bearing 
severely combined immunodeficient (SCID) male mice as the animal model to evaluate Res-
PdNP-4 nanoparticles ability to control or reduce prostate tumor size. The in vivo results of Res-
PdNP-4 showed a good dose response which was well tolerated by the animals, as no animal 
health problems and discomfort was observed as evidenced by body weight/eating habits of 
animals. Although further studies are required to determine a better dose to see increased 
xxiii 
 
efficacy. This study was performed through intravenous (IV) administration of the Res-PdNP-4, 
intraperitoneal (IP) delivery and direct injection into the tumor may show a better response as 
has been the case with many different types of nanoparticles. In conclusion, the therapeutic 
efficacy results showed that Res-PdNP-4 have significant therapeutic effect and are able to 
control the tumor size in comparison to the saline control and free resveratrol treated groups. 
This was due to the high corona of resveratrol-derived phenols and polyphenols on the PdNPs 
facilitating effectively enhanced delivery of resveratrol with high bioavailability, giving an 
advantage in tumor therapy. 
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CHAPTER 1 
INTRODUCTION  
1.1 Cancer 
Cancer continues to pose a tremendous challenge in society as being one of the main cause of 
death worldwide and contributes a major public health burden across the globe (Figure 1).
1–3
 
Cancer by definition is the uncontrollable cell proliferation that bypass the cell-cycle 
checkpoints; resulting in the creation of abnormal cells which become malignant tumors.
4,5
 The 
greatest number of cancer deaths is attributed by lung, breast, prostate, colorectal, liver, and 
stomach cancer (Figure 1)
4-6 
according to data reported by the International Agency for Research 
on Cancer with several entities such as the International Association of Cancer Registries, the 
National Center for Health Statistics (NCHS) - the National Cancer Institute (NCI), the Centers 
for Disease Control and Prevention’s (CDC’s), American Cancer Society, and the North 
American Association of Central Cancer Registries. In 2018, cancer was responsible for 9.6 
million deaths worldwide and new cases are projected to rise above 70% in the next few 
decades.
7
 Approximately 18.1 million new cases of cancer have been diagnosed globally in 
2018.
7–9
  
In 2015, Weir et al.
10
 predicted an annual increase in cancer incidences in the United States 
among men to be 24.1% (>1 million cases) and 20.6% among women (>900,000 cases) by 2020. 
These increases are expected to be from breast, prostate, kidney, liver, lung, thyroid, urinary 
bladder uterus cancers.
10
  The United States alone accounts for an estimated 1,762,450 new cases 
diagnosed in 2019 that is equivalent to about 4,800 new cases each day.
11
 Advancements in 
cancer treatment in recent years have showed promise in alleviating cancer, however, the cost of 
2 
 
cancer care is increasing at an exponential rate each year and this rise in health-care costs vastly 
represents a central challenge for governments and the private sectors.
12–14
 Moreover, late-stage 
cancer presentation and recondite diagnosis are common challenges that hinder the effectiveness 
of current treatment modalities due to the cancer’s continuous evolution.  
 
Figure 1: Cancer incidence worldwide in 2018. Breast, lung, prostate and colorectal 
cancers contribute a major public health burden across the globe.
9
 
In 2017, Fleming et al.
15
 and Sayed et al.
16
 reported evidence suggesting that low-income 
countries (less than 30 %) lack pathology services that are accessible in the public sector. A 
majority (~90%) of high-income countries have appropriate cancer treatment services,
4
 therefore, 
the economic impact of cancer is significant causing financial burdens to families, countries and 
3 
 
the world, with annual costs of cancer treatment that reached $1.16 trillion in 2010 (Figure 
2).
17,18  
 
Figure 2: Financial burden of cancer healthcare in the United States from 2010 to 2017.
17,18
 
The healthcare costs for cancer treatment are expected to increase exponentially as new and more 
advanced therapies are adopted as standard care for cancer treatments. Prostate cancer is an 
aggressive malignant tumour, reported to be the second-/sixth-leading cause of cancer-related 
death and the most diagnosed cancer in men in the United States and worldwide, respectively.
9,19
 
The mainstay of cancer therapy modalities include chemotherapy, surgery, radiation therapy, 
targeted therapy, hormone therapy, stem cell transplant, cancer immunotherapy, and a 
combination of modalities.
20
 Some of these modalities have shown promising results towards 
prolonging the quality of life; however, failures in these therapies are governed by dose-limiting 
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toxicities, lack of selectivity and specificity that leads to severe unintended side effects 
compromising the health and wellbeing of the patient. 
In the case of cancer immunotherapy which has received tremendous attention to date due to 
reported benefits of activating the immune system to defend itself against tumour cells.
21–25
 This 
has sparked global interests in cancer treatment, where the global cancer immunotherapy market 
in 2016 was valued at $45 billion.
26
 This market is projected to reach $152.83 billion by 2024, 
growing at a compound annual growth rate (CAGR) of 13.8% during the forecast period of 2018 
to 2024.
27
 The cancer cost conundrum for access to cutting-edge personalized cell-based 
therapies is an obstacle since the  majority of the global population cannot afford this treatment 
due to price trajectory.
28
 Moreover, the Agency for Healthcare Research and Quality (AHRQ) 
estimated that the direct medical costs (total of all healthcare costs) for cancer in 2015 was $80.2 
billion.
13
 Despite modern medical approaches in cancer treatment, a major clinical problem and 
cause of patient death is attributed by secondary cancer events led by tumour metastasis.  
1.1.1 Prostate cancer 
Prostate cancer is the most common malignancy among men worldwide and the most frequently 
diagnosed type of cancer in men in over 57% of the countries in the world.
9
 Prostate cancer is 
associated with significant morbidity (1.3 million cases) and mortality (359,000), representing 
the second most frequent cause of cancer-related deaths in male population in the world as 
shown in  Figure 3.
9,29,30
 About 11% of men (aged 65 or older) will be diagnosed with prostate 
cancer in their lifetime, this number is expected rise according to the Global Cancer 
Observatory.
9
 In the United States alone an estimated number of 174,650 new cases of prostate 
cancer and 31,620 deaths from prostate cancer are expected for 2019.
9,31,32
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Figure 3: World map representing the most common type of cancer mortality in 2018 among men. Prostate cancer is ranked 
second after lung. Adapted with permission from GLOBOCAN 2018. 
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Prostate cancer is a complex heterogeneous disease with diverse sets of hallmark capabilities that 
orchestrates prostatic tumorigenesis and metastasis (Figure 4). 
 
Figure 4: Prostate cancer tumorigenesis and metastasis from Stage I to Stage IV. The 
cancer cells grow within the prostate (Stage I and II), through the outer layer of the 
prostate into surrounding tissues (Stage III), and then to lymph nodes or other organs of 
the body (Stage IV). 
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1.1.1.2 Types of prostate cancer 
The type of prostate cancer is determined by the origin of the cancer: 
(i) Acinar and ductal adenocarcinoma 
The majority (95%) of prostate cancers are adenocarcinomas, which are the frequent and most 
common type of diagnosed cancer in men. Acinar and ductal adenocarcinomas develop in the 
gland cells that line the prostate gland and in the cells that line the ducts (tubes) of the prostate 
gland, respectively. The ductal adenocarcinoma proliferates more rapidly than acinar 
adenocarcinoma.
33
 
(ii) Transitional cell (or urothelial) cancer 
Approximately 4% of prostate cancers are arise from transitional cell carcinoma that develops 
from cells that line the inside of the tubes (ureters) which is part of the urinary tract, responsible 
for carry urine produced by the kidneys to the bladder and spreads into the prostate.
34
 It is rare 
solid malignant tumor that is highly aggressive and presents poor prognosis.
35
 
(iii) Squamous cell cancer 
This is a rare type of cancer develops from flat cells that cover the prostate and proliferates more 
rapidly than adenocarcinoma of the prostate. As demonstrated by Malik et al.36, Biswas et al.37 
and Brunnhoelzl and Wang
38
, squamous prostate cancer approximately makes up 0.5% to 1% of 
all prostate carcinomas and aggressive cancer with bony metastases. 
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(iv) Small cell prostate cancer 
Rare type of anaplastic prostate cancer (<1%) is a high-grade malignant neoplasm with 
neuroendocrine differentiation and one of the most aggressive malignancies of the prostate.
39,40
  
1.2 Diagnosis and current prostate cancer treatment 
The diagnosis of prostate cancer is mainly through monitoring prostate-specific antigen (PSA) or 
prostate-specific membrane antigen (PSMA) levels produced by normal and malignant cells of 
the prostate gland.
41,42
 The blood level of PSA/PSMA is elevated in men with prostate cancer, 
the PSA test is often in conjunction with a digital rectal exam, transrectal ultrasound, transrectal 
needle biopsy and these specify the appropriate type of treatment for a patient (Figure 5).
42–45
 
The standard of treatment for prostate cancer depends type of diagnoses that range from 
localized to metastatic cancer as shown in Table 1. However, many of the prostate tumors 
currently being diagnosed also include small, early stage, indolent, and low‐risk prostate cancer. 
Substantial majority men still undergo overtreatment to receive aggressive whole‐gland 
treatment with either surgery or radiation. 
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Figure 5: Systemic therapy landscape of prostate cancer progression.46,47
10 
 
Table 1: Standard healthcare treatment for prostate cancer 
Treatment Description Side-effects 
Expectant 
management 
Expectant management consists of watchful waiting and active surveillance 
of prostate cancer progression that includes treating symptoms with palliative 
intent focused on managing pain or urinary difficulty (e.g. urinary retention 
or hematuria) – candidates are typically older (>65 years).48 Active 
surveillance involves a series of monitoring prostate-specific antigen (PSA) 
levels and a combination of prostate biopsies and physical examinations to 
monitor cancer progression with curative intent.
43
 
May be more detrimental effects 
for younger patients with high 
risks of progression. 
Surgery Surgical removal of the tumor using three types of acceptable surgeries (i) 
radical prostatectomy (retropubic or perineal) by removing the prostate 
through an incision in the abdominal wall or in the perineum, respectively; 
(ii) pelvic lymphadenectomy (PLDN) – removal of the lymph nodes in the 
pelvis and (iii) transurethral resection of the prostate to remove tissue from 
the prostate using a resectoscope inserted through the urethra.
49–51
 
Erectile dysfunction, damage to 
nearby organs, and infections at 
the surgery site. 
1
0
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Treatment Description Side-effects 
Radiation 
therapy and 
radiopharmaceu
tical therapy 
Radiotherapies are the second major therapeutic modalities for prostate 
cancer. These utilizes a form of high-energy x-rays or other types of 
radiation (α- or β particles) to kill the cancer cells. The treatment strategies 
include external-beam radiotherapy (EBRT), hypofractionated radiation 
therapy, internal radiation therapy/brachytherapy – this involves inserting 
radioactive seeds (t1/2 = 60 days) at the prostate tumor site and monitoring 
tumor shrinkage via ultrasound guidance. Radiopharmaceutical therapy uses 
radioactive (e.g. radium-223) to treat prostate cancer that has metastasized to 
the bone.
52
 
Increased risk of having bladder 
and/or gastrointestinal cancer. 
Damage to nearby organs and 
infertility.  
Hormonal 
therapy 
Surgical removal of male hormones or silencing their expression through 
orchiectomy, androgen deprivation therapy (antiandrogens), abiraterone 
acetate, estrogens, luteinizing hormone-releasing hormone agonists and other 
drugs that prevent adrenal glands.
53
 
Impaired sexual function, loss of 
desire for sex, and weakened 
bones. 
Chemotherapy Treatment with drugs such as taxane (docetaxel and cabazitaxel) and 
platinum-based (cisplatin, carboplatin and oxaliplatin) chemotherapies that 
stop the proliferation of cancer cells.
54,55
 
Secondary systemic toxicity, hair 
loss and diarrhea. 
1
1
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Treatment Description Side-effects 
Immunotherapy 
 
Boosting or restoring the immune homeostasis against cancer. Sipuleucel-T 
and pembrolizumab used for programming a patient's immune system to 
target prostate cancer cells and destroy them.
45,56,57
 
Bone/muscle aches but can be 
resolved within a few days. The 
biggest challenge is the cost of 
the treatment. 
1
2
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The challenge of current prostate cancer therapies is hindered by the pivotal factors that 
constitute an ‘Achilles heel’ where the systemic side effects (such as urinary symptoms and 
sexual dysfunction) greatly outweigh the benefits of the treatment. There is an urgent need to 
develop multimodality approaches that simultaneously targets cancers at multiple levels.  
1.3 Significance 
Metal-based therapies such as platinum (Pt)-based antitumor chemotherapeutic drugs (cisplatin 
[cis-Pt(NH3)Cl2], carboplatin and oxaliplatin have been used as broad spectrum therapeutic 
agents to primarily treat solid tumors and these chemotherapeutic agents remain among the most 
widely used cancer therapies for myriad human cancers (Figure 6).
 58
 The quest for metal-based 
anticancer agents continues to attract significant attention because of the evidence that metals 
such as Pt show propensity to form DNA intercalating adducts which are generally not feasible 
through conventional drugs.
59,60
 Although cisplatin and its derivatives (carboplatin and 
oxaliplatin) are used in the vast majority cancer treatments for patients suffering from various 
forms of cancer, these Pt-based pharmaceuticals continue to pose vexing clinical problems such 
as gastrointestinal and cardiovascular toxicity, injury to renal tubular epithelial cells, 
emetogenesis, nephrotoxicity and others.
58,61,62
 Pt-based drugs are highly toxic with a lethal dose 
(LD) of 6.6 mg/Kg of body weight for cisplatin and the low tumor selectivity, specificity and 
solubility also contribute to its high toxicity.
63
 Moreover, cisplatin-resistant tumors cannot be 
treated through Pt-based chemotherapeutic agents.
64
 
To circumvent the challenges presented by Pt-based chemotherapeutic drugs, researchers have 
devoted significant amount of work in developing non-Pt metal ion complexes for cancer 
treatment. Palladium (Pd) complexes as anti-cancer drugs have been explored due to their 
14 
 
structural similarities and overlapping coordination chemistry with Pt as shown in Table 2.
58,65
 
Pd-based pharmaceuticals are being developed for use as the next generation metal-based 
anticancer drugs in order to overcome severe systemic toxic effects and drug resistance 
associated with cisplatin and its derivative chemotherapeutic agents.
58,66
  
 
(i)                       (ii)                                  (iii) 
Figure 6: Platinum chemotherapeutic drugs used for the treatment of solid cancer (i) 
cisplatin, (ii) carboplatin and (iii) oxaliplatin 
Table 2: Properties of Pd(II) and Pt(II) 
Property Pd(II) Pt(II) 
Dissociation pattern Slow Fast 
Density (g cm
−3
) 12.0 21.5 
Reactivity High Low 
Albeit, Pd(II) and Pt(II) have significant coordination chemistry similarities, Pd(II) complexes 
serve as suitable antitumor drugs over Pt(II) complexes mainly because of their high solubility.
67
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1.4 Palladium complexes used for cancer therapy 
Palladium is known to possess remarkable catalytic and optical properties, however; its medical 
applications have not been fully exploited.
68
 It is widely used as a versatile catalyst in a number 
of important reactions (e.g. C-C coupling reactions, hydrogen storage and sensing).
69
 Moreover, 
Pd exhibits exceptional electro-activity that can be harnessed for high-energy flux production.
70
  
However, Pd complexes have been used in the medical sector for several years. For example, 
palladium chloride complexes was previously prescribed for the treatment of tuberculosis, 
administered at 1 mg/kg body weight per day without presenting side effects.
71
 In the medical 
field, Pd has been used as an alloy component in dental appliances and radioactive isotope of Pd 
(
103
Pd seeds) are used for brachytherapy for melanoma and prostate cancer treatments.
72,73
  
Jahromi et al.
58
 reported Pd(II) dithiocarbamate derivatives complexes were effective against 
cisplatin resistant tumors. Noticeably, the chelating ligand was found to play a crucial role in the 
effectiveness of these complexes, since some Pd(II) complexes shown no significant antitumor 
efficacy. Furthermore, Jahromi et al.
58
 demonstrated that these complexes exhibited a low kidney 
toxicity compared to cisplatin, this was associated with the inability of kidney tubules proteins to 
replace tightly bound chelate ligands of Pd(II).  
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1.4.1 Types of Pd(II) complexes 
A variety of Pd(II) complexes have been investigated for their in vitro and in vivo anticancer 
activity against a number of tumors (Figure 7). 
(i) Trans-Pd(II) complexes - Abu-Surrah et al.65 reported that trans-Pd(II) complex 
(trans-[Pd{(R)-(+)-bornylamine}2Cl2]), when compared with cisplatin, showed 
similar antitumor activity against HeLa cells. Huq et al.
74
 found that trans-PdCl2L2 
where L = 2-hydroxypyridine, had a higher antitumor activity against resistant 
ovarian cancer cell lines. 
(ii) Pd(II) complexes bidentate ligands – square planar Pd(II)-selenite complex 
([(bipy)Pd(SeO3)]) was found to intercalate DNA through covalent bonding similar to 
cisplatin mode of action, results showed better cytotoxicity when compared to 
cisplatin.
65
 The N-N ligands (bipyridine and phenanthroline) based Pd(II) complexes 
have been reported to have lower half maximal inhibitory concentration (IC50) values 
than cisplatin against P388 lymphocytic leukemia cells.
75
  
(iii) Phosphine ligands coordinated Pd(II) complexes – The cyclopalladated complexes 
based on biphosphine ligands were reported to cause total destruction of the tumor 
cells (B16F10-Nex2 murine melanoma; Ehrlich ascites carcinoma and DU145 human 
prostate carcinoma (HTB-81)) at low concentration (<1.25 µM).76 
(iv) Pd(II) complexes with mixed donor atom ligands - 
[(Benzyl)Pd{bis(thiosemicarbazonate)}] is a thiosemicarbazide derivative that was 
found to have similar IC50 of cisplatin and still active against cisplatin-resistant cell 
lines.
77
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(v) Multinuclear Pd(II) complexes – a trinuclear complex [{trans-PtCl(NH3)}2-#-
{trans-Pd(NH3)(2-hydroxypyridine)-(H2N(CH2)6NH2)2]
4+
 was reported to have 
antitumor activity against cancer cell lines.
78
 This was found to be attributed to the 
formation of inter-strand GG adducts with duplex DNA which affects the integrity of 
the DNA leading to apoptosis. 
                        
(i)                                                      (ii)                                      (iii) 
                       
(iv)                                                                            (v) 
Figure 7: Palladium complexes that have been investigated for their activity against tumor 
cells (i) trans-[Pd{(R)-(+)-bornylamine}2Cl2, (ii) [(bipy)Pd(SeO3)], (iii) Pd(II) complexes 
bearing 1,2-bis(diphenylphosphino)ethane (dppe), (iv) [(Benzyl)Pd{bis(thiosemicarbazona 
te)}], and (v) [{trans-PtCl(NH3)}2-#-{trans-Pd(NH3)(2-hydroxypyridine)-(H2N(CH2)6NH2)2] 
4+
.
65
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1.4.2 Challenges associated with Pd(II) complexes 
The pharmaceutical design of Pd(II) complexes with anticancer activity are challenging, since 
Pd(II) is thermodynamically and kinetically less stable than Pt(II) complexes.
79
 Moreover, Pd(II) 
complexes have rapid ligand-exchange kinetics (10
5
 times faster than their corresponding Pt 
analogues)
65
 leading to very reactive species that hinders it’s overall pharmacological 
effectiveness.
80
 Therefore, it is important to take into consideration the high reactive nature of 
Pd(II) when developing Pd(II)-based pharmaceutical drugs, Abu-Surrah et al.
65
 suggested that 
Pd(II) antitumor drugs should be stabilized by strongly coordinated nitrogen ligand and suitable 
non labile leaving group to maintain structural integrity in vivo. However, rapid ligand exchange 
and hydrolysis is a major drawback of palladium complexes that limits their clinical translation. 
This can be overcome by the palladium nanostructures, to be discussed below.
79
 Isomerization of 
Pd(II) complexes from trans to cis conformation affects their bioactivity.
81,82
 In general, several 
studies indicated that trans-Pd(II) complexes are more effective than cis-Pd(II) complexes and 
show activities that are comparable or superior to those of cisplatin against tumor cells.
65
   
1.5 Plant-derived agents as anticancer pharmaceutical drugs for cancer therapy 
Biologically active compounds isolated from plants are considered to be nutraceuticals because 
they possess some medicinal properties which can lead to the treatment of a variety of certain 
diseases as shown in Scheme 1. The use of medicinal plants for treating diseases dates back to 
Egyptians, Greek and Romans civilizations, however, 3000 years ago; Hippocrates coined the 
phrase “Let food be thy medicine and medicine be thy food” – a notion about the therapeutic 
application of food.
83
 This is justified by modern medicine, such as plant derived chemotherapies 
19 
 
used for the treatment of various disorders such as cancer. There are four classes of plant-derived 
anticancer and other disease-related drugs currently in the market as shown in Table 3.
84
  
Modern medicine is focused on the fundamental premise of understanding the pharmacokinetics 
and pharmacodynamics in relation to the dosimetry of a drug rather than complex formulations 
by medicinal practitioners (e.g. herbalist and traditional healers) that lack reproducibility 
between batches. All plant-derived anticancer drugs on the market are based on reverse 
engineering and pharmacology as shown in Scheme 1 to isolate the single most active compound 
and determining their molecular mechanism and mode of action.
85
 This is dependent on the 
quality, purity and quantity of the isolated active compound from the medicinal plant and further 
characterization to determine the pharmacokinetics, pharmacodynamics, metabolic fate, efficacy 
and safety, dosimetry, drug interaction, immunogenicity and associated side effects.  
However, most drugs that reach the market are based on the positive statistical correlations, 
safety and efficacy on a large population. As we encroach more into approaches geared at 
personalized medicine and recent discoveries in immunotherapy – the future of modern medicine 
is immunomodulation and regenerative medicine to strengthen the immune system. Medicinal 
plants serve as reservoirs for novel bioactive chemical entities as potential candidates for the 
development of anticancer drugs due to their pleiotropic actions specifically against tumor cells 
without affecting normal cells.
86
 Several nutraceuticals have been reported for playing a pivotal 
role by inhibiting the progression and development of cancer trough convulsing cancer cell 
activating proteins/enzymes and signalling pathways.   
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Scheme 1: Reverse engineering and pharmacology of plant-derived anticancer drugs 1) food as a source of nutrients, 2) 
chemical extraction from plant material, 3) purification and identification of isolated compounds, 4) identification of active 
compound, 5) in-vitro cellular studies, 6) in-vivo anticancer pre-clinical studies, 7) bioinformatics and immunological studies 
and 8) clinical studies for prospective use as a cancer therapeutic drug.  
2
0
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Table 3: Plant-derived drugs in the market used for the treatment of cancer and other-related diseases 
Class Anticancer 
drugs 
Structure Source Therapeutic 
benefits 
Company Reference 
Taxanes 
Paclitaxel 
(Taxol®) and 
Docetaxel 
(Taxotere®) 
 
(Paclitaxel) 
Plant 
alkaloid 
derived from 
the Pacific 
yew (Taxus 
brevifolia). 
Docetaxel is 
the synthetic 
derivative of 
paclitaxel, 
10-deacetyl 
baccatin III 
as the 
precursor. 
Mitotic inhibitor 
which binds 
microtubulin 
preventing 
chromosomal 
missegration, 
apoptotic cell death 
and mitotic arrest.
87
 
It is used as a cancer 
chemotherapy for 
breast, lung, 
pancreatic, prostate, 
melanoma and 
ovarian cancer. 
 
Python Biotech, 
LLC 
(United States) 
Weaver
87
; 
Pandey et al.
88
 
2
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Class Anticancer 
drugs 
Structure Source Therapeutic 
benefits 
Company Reference 
Vinca 
alkaloids 
Vincristine 
(Oncovin®), 
Vinblastine 
(Velban®) and 
Vindesine 
(Eldisine®) 
 
 
(Vincristine) 
Vinca 
alkaloid 
isolated from 
Vinca Rosea 
and 
Catharanthu
s roseus 
Antimicrotubule 
agent that blocks, 
thereby arresting cell 
cycle at metaphase 
89
 
and used to treat 
breast, leukemia, 
lymphoma, small 
cell lung, myeloma 
and head and neck 
cancer.
86
 
BTP 
Pharmaceutical
Co Limited 
(China), 
Minakem H.P 
(Germany) and 
Eli Lilly Sa 
County Cork 
(South Africa) 
Holland et 
al.
89
; Sarin et 
al.
90
 
Camptoth
ecin 
derivativ
es 
Camptothecin 
(Camptosar®) 
and Irinotecan 
(Onivyde®)  
 
(Camptothecin) 
Isolated from 
the bark and 
stem of 
Camptotheca 
acuminata 
 
Topoisomerase 
inhibitor used for the 
treatment of 
metastatic colon. 
Sichuan JingYu 
Chemical Co., 
Ltd and 
Pengzhou 
Maoyuan 
Biochemical 
(China) 
Venditto and 
Simanek
91
 
2
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Class Anticancer 
drugs 
Structure Source Therapeutic 
benefits 
Company Reference 
Epipodop
hyllotoxi
ns 
Etoposide 
(Etopophos®) 
and  
Teniposide 
(Vumon®) 
 
(Etoposide) 
Semisyntheti
c derivative 
of 
podophylloto
xin of 
extracted 
from the 
mandrake 
root 
Podophyllum 
peltatum 
Topoisomerase 
inhibitor used treat 
lung, testicular 
cancers, lymphomas 
and leukemia. 
 
 
 
 
 
 
 
Cipla (India) 
and Jiangsu 
Hengrui (China) 
Kim et al.
92
 
and Liang et 
al.
84
 
2
3
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Other disease related  drugs 
Class Anticancer 
drugs 
Structure Source Therapeutic 
benefits 
Company Reference 
Cephalot
axus 
alkaloids 
Omacetaxine 
mepesuccinate 
(Synribo®) 
 
Isolated from 
Cephalotaxu
s 
harringtonii 
 
Tyrosine kinase 
inhibitor used for the 
treatment of chronic 
myeloid leukemia. 
Teva 
Pharmaceutical 
(United States) 
Alvandi et 
al.
91
 
Anticancer drugs Structure Source Therapeutic 
benefits 
Company Reference 
Epidiolex 
 
Cannabidiol 
drug from 
the cannabis 
plant  
to treat seizure 
disorders 
GW 
Pharmaceuticals 
FDA
93
 
 
2
4
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1.6 Resveratrol 
Resveratrol (3,5,4′-trihydroxy-trans-stilbene) is a non-flavonoid polyphenolic compound 
predominantly found in the skin of red grapes and various red wines.
94
 Resveratrol (Res) was 
investigated because of the “French paradox” – that is, the low prevalence of coronary heart 
disease were reported in a population of people in Southern France as a result of high red wine 
consumption.
95–97
  This posed extensive research on Res, thus several studies have been focused 
on demonstrating the cardioprotective properties of Res against plaque development in various 
animal models of atherogenesis.
98–100
 Nonetheless, like most effective polyphenols, low 
bioavailability hinders its effectiveness towards clinical translation. A minimal fraction 
(approximately ~ 2–4 μM in the blood) of ingested Res reaches mammalian tissue and to some 
extent the tumor.
101
 Therefore, the increased delivery of Res to the tumor is paramount to 
improving its bioavailability for an increased therapeutic effect against cancer and other related 
diseases. Coimbra et al.
102
 encapsulated Res in liposomes to increase its bioavailability and 
reduce their enzymatic degradation.
94
  
A pharmacokinetic study of Res was carried out by Ortuno et al.
103
 demonstrated that Res from 
natural grape products had a higher absorption in vivo as opposed to tablet supplements, thereby 
conferring  the importance of the delivery matrix for Res which imposes its bioavailability.
104
  
Moreover, Res is a lipophilic molecule that can easily cross through membranes and target 
membrane receptors (such as estrogen receptor alpha and beta (ER-α and ER-β), integrin αvβ3, 
androgen receptor) that can increase its intra-tissular levels.
105–109
 According to some studies, 
Res is known to be a chemopreventive molecule with various health benefits, such as anti-
angiogenic, anti-diabetic, anti-obesity, anti-inflammatory, anti-oxidant, anti-proliferative, anti-
26 
 
viral, cardiovascular, anti-cancer and neuroprotective properties (Figure 8).
83,110–112
 As a natural 
anticancer agent, Res participates in the regulation of a number of signaling pathways resulting 
in suppression of adhesion, thus limiting invasion and metastasis of tumor cells.
109
 Furthermore, 
tumor cell proliferation is affected due to induction of apoptosis, differentiation and reduced 
angiogenesis facilitated by Res’s pleiotropic effects.112 Patel et al.113,114 reported evidence that 
suggested that Res can be metabolized into stable sulfate-conjugated forms in human colorectal 
cells which in turn can provide beneficial effects in vivo in the form of generating parental 
compounds. 
27 
 
 
Figure 8: Clinical benefit of resveratrol in cancer, cardiovascular diseases, chronic inflammation, diabetes, neurological 
disorders and non-alcoholic fatty liver disease (Refer to the Abbreviation section for complete definition of the abbreviations). 
2
7
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1.6.1 Anticancer mechanisms of resveratrol bioactivity 
The chemical structure of Res is analogous to the structures of diethylstilbestrol, 17-β estradiol 
and piceatannol, which are synthetic estrogen that can binds to the estrogen receptor alpha (ERα) 
as shown in Figure 9.
115,116
 This suggests that Res can act as an agonist of ER and thereby 
increase the transcription of estrogen-responsive reporter gene.
115,117
 Structural ligand-specific 
response insight into partial agonist and antagonist action of phytoestrogen Res on ERα ligand 
binding domain was further investigated by Chakraborty et al.
118
 using molecular modeling and 
atomistic simulations that confers chemoprotective properties in different cell types. Their 
findings revealed that Res can bind in both the antagonist and agonist conformations with ERα 
through the Helix 12 in the ligand binding pocket.
118–120
   
               
                         
Figure 9: Chemical structure of (i) 17-β estradiol, (ii) Diethylstilbestrol, (iii) Resveratrol 
and (iv) Piceatannol, the red colored structure show the homology between these 
compounds. 
(i) (ii) 
(iii) (iv) 
A 
A A 
B 
B 
B 
B A C 
D 
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Studies by Uberti et al.
121
 and Cipolleti et al.
122
 demonstrated that Res binds to ERα and ERβ 
receptors through a biphasic effect on cell proliferation and suppressing growth. These results 
also showed that Res inhibited cell proliferation in ER-negative cancer cell lines. Walle et al.
123
  
and Dandawate et al.
124
 reported that Res inhibits the proliferation of preneoplastic lesions by 
affecting signaling pathways through the activation of the de novo ceramide synthesis 
pathway.
125
 A number of human cancer cell lines (i.e. colon, breast, liver, lung, pancreatic, 
prostate and skin) against Res have been investigated and results showed the inhibition of cell 
proliferation, apoptosis induction and blocking cell cycle progression.
126–128
  
Res was found to inhibit the transcriptional activation of the carcinogen-activating enzyme 
(CYP1A1), which is responsible for preventing cancer at the initiation stage according to 
reported by Ciolino et al.
129
 Res was reported to be a cyclooxygenase-2 (COX-2) inhibitor which 
is an enzyme induced during carcinogenesis and inflammation.
120,130
 Treatment with Res was 
shown to significantly decrease COX-2 expression related to the inhibition of nuclear factor 
kappa-light-chain-enhancer of activated B cells (NF-κB) and COX-2 has been suggested to play 
a role in p53-dependent apoptosis in cancer cells, thereby showing antitumor properties, 
conferring its chemopreventive properties.
131,132
  
A number of studies have also reported Res to have antiaging properties, Pearson et al.
133
 and 
Bhullar et al.
134
  showed that elderly mice treated with Res had a beneficial effect in increasing 
their lifespan but not midlife mice. Kovacic and Somanathan
135
; Hsieh and Wu
136
 and Salehi et 
al.
115
 reported that the biological activities of Res were primarily attributed to the structural 
integrity of Res. The trans-Res with an ortho-diphenoxyl or para-diphenoxyl having a 4’-
hydroxyl and double bond showed a higher chemopreventive activity than the cis-Res 
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configuration.
137,138
 Res has been shown to participate in the sirtuin (SIRT) pathway which 
regulates apoptosis, cell-cycle regulation (through caspase-3 activation and Bax upregulation), 
cellular differentiation and proliferation, DNA damage, immune responses and induces 
autophagy via the inhibition of the hosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)/Protein 
kinase B (AKT)/ mammalian target of rapamycin (mTOR) pathway.109,112,120 This was validated 
by Zhao et al.
139
 demonstrating that Res induces autophagy through the inhibition of 
STRT1/AMPK-mTOR pathway. 
The laminin receptor modulates angiogenesis, enhanced invasive and metastatic potential of 
tumor cells (breast, prostate, lung, colon and etc.). Prostate tumor cells overexpress laminin 
receptors on their cell surface than normal cells and this can be exploited as a target for drugs.
140
 
Res has been reported to target progesterone-responsive collagen-laminin receptor α1 integrin. 
Therefore laminin receptor can be a target molecule for Res. Han et al.
141
 demonstrated that the 
anticancer of Res analogs and epigallocatechin gallate (EGCG) could be mediated by the 
activation of common receptor binding sites.  
Chemical metabolism and inhibitor for key proteins in signal transduction pathways (e.g. 
activator protein-1, mitogen-activated protein kinases (MAPK), cyclin dependent kinases, matrix 
metalloproteinases (MMPs), cyclins, AP-1, cytokines, COX-2 proteins and NF-κB are facilitated 
by the antioxidant activity of Res.
142–144
 Elshaer et al.
120
 suggested that resveratrol-induced 
apoptosis occurs through a variety of p53-dependent and p53-independent pathways, expression 
of pro-apoptotic Bax with concomitant inhibition of anti-apoptotic Bc1-2 protein (Figure 10). 
Moreover, the mitochondrial pathway has been implicated by resveratrol-induced apoptosis via 
Bax/Bcl2 ratio changes leading to the loss of mitochondrial transmembrane potential (MTP) with 
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subsequent release of cytochrome C followed by caspase cascade (caspase 3 and 9) results to 
apoptosis.
128
 The Pro-oxidant activity of Res is due to the hydroxylation that initiates a cellular 
apoptotic cascade through tumor necrosis factor (TNF)-related apoptosis-inducing ligand 
(TRAIL).
145
 Frazzi and Guardi
112
 mentioned that Res further participates within the 
mitochondrial apoptotic pathway which plays a crucial role during tumor death through changes 
in mitochondrial membrane potential leading in the subsequent release of cytochrome c in 
different tumor models.
146
  The epithelial–mesenchymal transition (EMT) plays a crucial role in 
tumorigenesis essential for metastasis, Res suppresses metastasis by modulating EMT-related 
factors (e.g. E-cadherin, N-cadherin, vimentin, MMP-2, and MMP-9) via the PI3K/Akt/NF-κB 
signaling pathway.
120,147
 
Catalgol et al.
94
 and Park et al.
148
 reported that Res regulates SIRT1 transcription and activity, 
this was further endorsed by Dai et al.
149
 who reported that Res is a therapeutic sirtuin activating 
compound for the overexpression of SIRT1 which inhibits several oncogenes and enzymes such 
as the cyclic adenosine monophosphate (cAMP)-degrading phosphodiesterases, resulting in 
induced apoptotic tumor suppression.
149,150
 Res is further involved in a cascade of pathways, as 
an activator for MAPK (MEK1/2) which catalyzes the phosphorylation of ERK1/2 which 
meditates cell proliferation and apoptosis.151,152 Res inhibits angiogenesis by suppressing the 
expression of vascular endothelial growth factor (VEGF), thereby downregulating hypoxia-
Inducible Factor 1α (HIF-1α).153 The onset of apoptosis can be triggered by the production of 
reactive oxygen species (ROS) and Res has been implicated in ROS production that seems to be 
a relevant mechanism of Res-induced cell death.
154,155
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Figure 10: Schematic diagram that depicts the cancer therapeutic mechanism of resveratrol, inducing apoptosis through p53-
dependent activation of pro-apoptotic proteins (Bax, NOXA, and BUMA). Moreover, resveratrol upregulates Sirt1 and AMPK 
that induces cancer cell death by autophagy. The downregulation of the TGF-β1/Smads, Wnt/β-catenin and PI3K/Akt/NF-κB 
pathways by resveratrol inhibits EMT metastasis and HIF-1α/MMPs dependent inhibits VEGF angiogenesis.   
 3
2
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In light of the reports of Res being a natural chemopreventive and chemotherapeutic agent 
against cancer and other-related diseases, this is supported by growing in vitro and in vivo data 
demonstrating the inhibitory effects of Res on a wide variety of human tumor cells.
155
 Antitumor 
and anti-metastatic properties of Res are due to the inhibition of DNA synthesis, 
neovascularization and angiogenesis.
157,158
 This data was corroborated by recent evidence 
demonstrating that cells undergo cell cycle arrest at the G0/G1 and S-G2/M phase and apoptosis 
following Res treatment.
112,159,160
 
1.6.1.1 Resveratrol delivery through various mode of administration 
The cancer chemopreventative action of Res replies mainly on the delivery and bioavailability of 
Res to achieve a high therapeutic effectiveness. There are several routes of administration for 
Res:  
(i) Buccal administration – Res absorption directly via the mucous membrane of the 
mouth. The drawback of this method is due to Res’s low solubility which limits the 
absorbable amount through the buccal mucosa.
159
  
(ii) Oral administration - as a tablet restricts the bioavailability because Res is 
metabolized rapidly into its glucuronate and sulfonate conjugates derivatives in the 
intestine and liver.
161
  
Nanoemulsions are 20 to 200 nm formulations that are composed of two immiscible liquids that 
form a single phase through emulsification method.
83
 This mode of delivery enhances better 
retention for effective delivery of Res to the tumor. This can be achieved through the use of 
Liposomes which are spherical phospholipids composed of lipid bilayers as an advanced delivery 
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system. Godin et al.
162
 reported the effective delivery of quercetin through the blood brain barrier 
for an increased therapeutic antitumor efficacy. Machida et al.
163
 and Sanli et al.
164
 demonstrated 
the delivery of Ginseng and curcumin phytosomes (phospholipid complexation) provided a 
better therapeutic efficacy attributed by elevated bioavailability and increased antioxidant 
activity. Microspheres (1 to 1000 µm vesicular particles) have been reported as effective carriers 
for camptothecin for providing a prolonged anticancer effect.
163–166
 Transfersomal drug delivery 
of vincristine, tamoxifen, stavudine and interferon-α have been reported by Bhasin and 
Londhe.
167
 
1.6.2 Pitfalls and limitations associated with resveratrol delivery 
The stability of the formulation without compromising the anticancer therapeutic efficacy of Res 
can be a great challenge. The above-mentioned delivery systems must confine to release Res 
only at the site of delivery, thus a suitable system must take into consideration the 
pharmacodynamics and pharmacokinetics of the system. Insight about the pharmacokinetic 
mechanism can be performed through in vitro tests, however, the data do not provide any 
information about Res cellular uptake and metabolic responses.
83
 Another major challenges is 
geared towards lack of recognition by pharmaceutical companies, industrial investments and 
federal funding in nutraceutical research, as nutraceutical formulations are not perceived as 
medicine.
85
 Obeid et al.
168
 pharmaceutical companies have embraced synthetic and combinatorial 
technologies in favor of drug discovery programs based naturally derived candidate molecules. 
We cannot conceal the body of evidence from research papers that have demonstrated the crucial 
role of nutraceuticals in the prevention and treatment of various diseases. Moreover, the 
incorporation of a nutraceutical such as resveratrol into a drug formulation serves as an effective 
35 
 
alternative for patients who are unwilling to go through current chemotherapies (such as 
cisplatin) which affect the quality of life due to their toxicity. Thus, creating a paradigm shift in 
medicine relinquishing cancer management towards true health care focused at treating the root 
cause of the cancer rather than its systematic symptoms. 
1.7 Nanoscience and nanotechnology 
Nanoscience is the study of the properties of matter at a nanoscale (1-100 nm); it is an 
interdisciplinary and multidisciplinary field that integrates different knowledge and methods 
from various disciplines such as biology, chemistry, physics, materials science and engineering. 
Nanotechnology is the application of nanoscience through the design, manipulation and 
fabrication of materials by atom-by-atom or molecule-by-molecule while maintaining their shape 
and size at a nanoscale. This application offers materials with enhanced chemical and physical 
properties different from the same bulk material counterparts utilized in a variety of applications 
such as electronics, food agriculture, textiles, renewable energy, environmental, industrial, 
biomedical and healthcare sector.  
1.7.1 Nanotechnology in medicine 
Nanotechnologies utilized in the biomedical field have improved a myriad of applications for 
diagnostics and targeted therapy for drug delivery. This is due to the peculiar physiochemical 
properties of nanomaterials, which is attributed by increase surface-to-volume ratio. A variety of 
methods using hazardous substitutes (such as sodium borohydride, hydrazine) have been used to 
synthesize metallic nanoparticles with multifactorial interaction capabilities with biological 
systems that can result in toxic side effects impeding their clinical translation in the 
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pharmaceutical and medical fields. The use of nanocarriers for delivery has demonstrated 
effectiveness in delivering a number of pro-drugs (doxorubicin).
169
 
1.7.2 Application of palladium nanoparticles (PdNPs) 
Palladium (Pd) is amongst the rare and precious metal (such as ruthenium, rhodium, osmium, 
iridium, and platinum) that belongs to the Platinum group elements.
170
 Moreover, Pd is 
predominately used as a catalyst in automotive catalytic converters, but recently has found 
applications in the electronic, engineering and biomedical sectors.
171
 Recent studies, have 
demonstrated Pd to have a propensity to adsorb hydrogen which has led palladium nanoparticles 
(PdNPs) to be utilized in hydrogen storage, catalysis and in fuel cells during electrochemical 
reactions.
170,172,173
 Different methods for palladium nanoparticles synthesis have been reported 
which include chemical reduction, metal vaporization, laser ablation, sonochemical and sol-gel 
process, however these methods generate hazardous byproducts and particles.
172
  
Chitosan-graphene material doped with PdNPs have been used in the development of biosensors 
for determining of glucose levels.
174
 In medicine, Pd nanostructures have been reported as 
prodrug activator and photothermal agents for photothermal therapy (PTT) and as anti-
tumor/antimicrobial agents, respectively.
70
 The PTT is through an external near-infrared (NIR) 
light source which emits a photon that penetrates through tissue to excites the tumor localized Pd 
nanostructures to produce heat, thereby causing tumor death as shown in Figure 11.
175–178
 
Combinational therapy using PdNPs with site-specific ligands as a NIR photo-absorber has a 
number of advantages such as precise spatial-temporal selectivity and effective eradication of 
tumor cells. Work by Rubio-Ruiz et al.
179
 demonstrated a high precision photothermal ablation 
using biocompatible PdNPs.  
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Figure 11: A schematic representation of PdNPs photothermal therapy, where the external 
NIR laser excites the PdNPs to generate heat for hyperthermia. 
Rubio-Ruiz et al.
179
 further reported that NIR irradiated PdNPs conjugated with histidine 
significantly resulted in a higher temperature increase than PdNPs without histidine. This was 
postulated to histidine’s aromatic ring thus increasing the NIR light absorption, which promoted 
their photothermal capabilities.
180–182
 Laser microscopy-patterned analysis revealed that 
squamous cell carcinoma SSC-GFP cells irradiated with NIR laser alone were not susceptible 
compared to cells labelled with PdNPs and NIR irradiated.
179,183,184
 An in vivo xenograft tissue 
ablation study by Rubio-Ruiz et al.
179
 on CD-1 nude mice showed that tumor xenograft 
composed of cancer cells with PdNPs induced photothermal tissue ablation. 
Bharathiraja et al.
70
 synthesized a multimodal complex (water-soluble chitosan coated 
biocompatible PdNPs conjugated with RGD (arginine-glycine-aspartic acid) peptide for photo-
based imaging and therapy. The results obtained showed that the RGD peptide-linked, chitosan-
coated PdNPs (Pd@Chitosan-RGD) enhanced photothermal therapeutic effects under 808 nm 
laser irradiation and even after 5-cycles of irradiation the Pd@Chitosan-RGD maintained their 
Pd nanoparticles 
NIR light source 
Therapeutic efficacy 
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integrity. A vast pool of publications have demonstrated that PdNPs are ideal nanotheranostic 
candidates for enhanced photoacoustic imagining and photothermal therapy for tumors utilizing 
a non-invasive NIR laser.
70,180
  The benefit of NIR irradiation lies in water molecules having 
minimal absorbance around the NIR region, thereby preventing damage to healthy surrounding 
tissues due to overheating. Reale et al.
185
 and Iavicoli et al.
186
 have reported that PdNPs further 
demonstrated to increase the levels of cytokines (↑ IFN-γ release) as key mediators for their pro-
inflammatory action. 
1.7.3 Palladium nanoparticles targeted cancer therapy 
1.7.3.1 Toxicological effects of PdNPs 
Studies that investigate the toxicology of nanomaterials and PdNPs are on the cornerstone. The 
toxicity of PdNPs have been evaluated in vitro, ex vivo and in vivo models to assess a number of 
parameters which include cell viability, cytokine release, cell cycle dysfunction, oxidative stress 
reaction, DNA damage and the release of inflammatory mediators as shown in Table 4. 
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Table 4: Toxicology of palladium nanoparticles 
Type of 
PdNPs 
Experimental design Parameters 
investigated 
Results Reference 
In vitro 
1–12 nm Barley (Hordeum 
vulgare) seeds were 
cultivated in a 
hydroponic system 
containing a nutrient 
solution supplemented 
with 0–50 μM PdNPs 
for 1 week. 
Leaf length Leaf length: ↓ at 
≥40 μM of PdNPs 
compared to 
untreated plants 
(length: 115 mm vs 
125 mm, 
respectively).   
Battke et al.
187
 
Pd/magnetite 
nanoparticles 
(20–30 nm) 
 
Rainbow trout gills 
(RTgill-W1) cells were 
treated with 5–25 mg/L 
PdNPs for 72 h. 
 
 
 
 
Cell viability Metabolic activity 
and membrane 
integrity: ↓ after 1 
h, however, cell 
viability was fully 
restored after 72 h. 
Potthoff et 
al.
188
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In vivo  
10 ± 6 nm 
Female Wistar rats (n. 
5 per group) were 
treated with a single 
intravenous injection 
of 0-12 µg/kg PdNPs 
dose from day 1, 30 & 
60. Serum cytokines 
were assessed after the 
90
th
 day post exposure. 
Effects on 
the immune 
system 
Treatment at 12 
µg/kg PdNPs: ↓ 
IL-1α, IL-4, IL-6, 
IL-10, IL-12 and 
GM-CSF 
Iavicoli et 
al.
186
 
Female Wistar rats (n. 
4 per group) were 
treated with a single 
intravenous injection 
of 0-12 µg/kg PdNPs. 
Sex hormones (E2, 
FSH, LH, P and T) 
levels were analyzed 
after 14 days of 
exposure. 
Effects on 
the 
endocrine 
system 
Treatment at 12 
µg/kg PdNPs: ↓ E2 
and T while, ↑ 
FSH, LH, and P 
levels 
Leso et al.
189
 
E2, estradiol; FSH, follicle-stimulating hormone; GM-CSF, granulocyte-macrophage colony 
stimulating factor; IL, interleukin; LH, luteinizing hormone; P, progesterone; T, testosterone. 
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The results mentioned in Table 4 are based on studies that produced the tested PdNPs using 
chemical reagents such as sodium borohydride (NaBH4) as the reducing agent. Thereby, 
producing PdNPs that are not biocompatible increases human health and environmental risks. To 
overcome this challenge, alternative methods of synthesis are required, hence Green 
Nanotechnology a technology used to develop ecofriendly biocompatible materials to minimize 
human health and potential environmental risks. 
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CHAPTER 2 
GREEN NANOTECHNOLOGY 
Green nanotechnology is development of ecofriendly nanomaterials using plant bioactive 
compounds (phytochemicals, carbohydrates, etc.) rather than toxic chemicals (e.g., sodium 
borohydride, hydrazine, sodium citrate, etc.) to minimize side effects on human health, toxic 
waste and potential environmental risks. The utilization of green chemistry in the synthesis of 
nanoparticles have endowed them with biocompatibility, environmentally healthy, and stability 
in physiological solutions that mimic in vivo conditions, as well as facilitating further 
modification for specific-targeting therapies.
1–4
 Nanotechnologies bring about a paradigm 
advantage in packaging, storage, delivery and enhancing the bioavailability of active 
phytochemicals from various plants and herbal sources. Professor Kattesh Katti’s laboratory has 
pioneered the application of green nanotechnology for the development of nanoparticles of gold, 
silver, palladium and a host of other metallic precursors.
5–8 
That is, abiding by the 12 design 
principles of green chemistry outlined by Anastas and Warner within the American Chemical 
Society.
9
 
2.1 Green nanotechnology in cancer therapy – combinational modality 
An efficient strategy for overcoming metastasis is through combinational therapy that makes use 
of a natural cancer chemopreventive agent as an adjuvant treatment to complement existing 
therapy. The use of green nanotechnology provides an alternative solution that can surpass 
current obstacles for cancer treatments,
4,10,11
 thereby, attaining the maximum therapeutic efficacy 
against tumor cells with the minimum concentration of the nanodrug.
12
 Green nanotechnology 
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allows the development of nanoparticles through direct interaction of electron-rich anti-oxidants 
of plant origin.
13,14,21,20
 Gurunathan et al.
15
 demonstrated the use of leaf extract of Evolvulus 
alsinoides for the synthesis of palladium nanoparticles and reported then to be in vitro efficacy 
against A2780 human ovarian cancer cells. Moreover, the results revealed that the anticancer 
mechanism of the synthesized particles was through increased leakage of lactate dehydrogenase 
(LDH), elevated levels of reactive oxygen species (ROS), induced autophagy and autophagic cell 
death confirmed by transmission electron microscopy (TEM). The loss of mitochondrial 
membrane potential (MMP) and enhanced caspase-3 activity followed by DNA fragmentation 
accessed using terminal deoxynucleotidyl transferase (TdT) dUTP Nick-End Labeling (TUNEL) 
assay was attributed to PdNPs.
15
 There are currently ongoing efforts on the development of 
metallic nanoparticles as antineoplastic agents for a myriad of cancers. It is apparent from the 
above mentioned data that both the metal and the ligand determine the overall biological activity 
of the nanoformulations. The principle of suitable cancer therapy is not based on a single 
therapeutic intervention but on the pivotal philosophy of restoring homeostasis.
16
 
2.2 Green synthesis of palladium nanoparticles (PdNPs) 
The synthesis of palladium nanoparticles has been previously reported using various plants 
extracts (black pepper, tea, soybean, seaweed and other plant materials).
4,7–10,13,14,17–31
 The use of 
a single bioactive compound from the extracts facilitates the reproducibility of the synthesized 
nanoparticles of the same size and shape optimally suited to penetrate tumor vasculature 
associated with leaky blood vessels, which are manifested in all human tumors.
32
 This can be 
capitalized by synthesizing nanoparticles that are conjugated/encapsulated by natural anticancer 
agents as a combinational therapeutic strategy.  
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Resveratrol (Res) has three hydroxyl groups that can serve as electron donors to transform 
palladium metal salts into zero-valent palladium nanoparticles.
4
 Moreover, in the case of 
hydrogen bonds formed in phenoxy radicals, phenoxy radical oxygen can act as a proton 
acceptor in the presence of substituents that can serve as proton donors.
33
 The flavonoid B-ring 
of Res is more important than A-ring from a bond dissociation enthalpy (BDE) - represents the 
ease of hydrogen donation of phytochemicals; this is because the radical structure formed after 
H-atom abstraction from the 4′-OH group can be stabilized by the resonance between the two 
rings for strong electron-donating groups.
34,35
 The nucleophilic and electrophilic sites in Res are 
expressed in term of different color codes as shown in Figure 12.
33,34,34
  
   
Figure 12: Resveratrol A- and B-ring, and its molecular electrostatic potential (MEP), 
where the deep red color indicates an electron-rich site, whereas deep blue indicates an 
electron-deficient site. 
The electrostatic potential of a molecule indicates charge distribution of the reactive site of a 
molecule as an indicator of ligand binding. Moreover, the MEP reflects the dominant role of –
OH groups, with the negative (red) and positive (blue) potentials. The density functional theory 
(DFT) calculates BDE to determine the measure of the strength of a chemical bond O–H. The 4-
OH of Res has a BDE of 325.7 kJ mol
-1
, while 3-OH and 5-OH are 348.2 and 353.6 kJ mol
-1
, 
A 
B 
4’ 
5 
3 
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respectively.
35,36
 The hydroxyl group with a lowest BDE is more reactive; therefore, 4-OH group 
has highly condensed electron density area localized over the oxygen atoms with electron lone 
pairs along with the ionization potential (IP) and electronegativity of the resveratrol play an 
important role in chemical reactivity behavior.
36
 The IP of Res is 155.68 kcal mol
−1
 representing 
the ease of electron donation with a highest occupied molecular orbital (HOMO) energy at -7.5 
eV and lowest unoccupied molecular orbital (LUMO) at 2.53 eV.
34,37
 
The large surface-to-area ratio and extraordinary surface kinetics of atoms that make up the 
nanoparticles (gold, palladium, iron oxide and various nanoparticles) allow highly effective 
loading of anticancer phytochemical compounds in their nascent form onto the surface of 
nanoparticles.
38
  The strong propensity of phytochemical-conjugated nanoparticles (size range: 
15-30 nm) to internalize into tumor cells, through a combination of pathways (e.g., endocytosis 
and phagocytic).
10
 This allows for efficient transport and delivery of a reservoir of 
phytochemicals conjugated to the nanoparticles into the cellular matrix. Several studies have 
shown that Res exerts antimicrobial and antioxidant activities, which extend to anti-tumor 
properties, inhibitory effects on type II 5α-reductase (prostate-specific, membrane-associated 
enzyme that catalyzes the conversion of testosterone to dihydrotestosterone) in vitro,
 
and in vivo 
growth-inhibitory activity against ascitic fibrosarcoma.
21,22,39
 Thereby, Res can be a competitive 
inhibitor of the type II steroid 5α-reductase used to treat benign prostatic hyperplasia.  
Res has been reported to suppress M2-like polarization of tumor-associated macrophages 
(TAMs) which is associated with pro-tumoral features, this subsequently inhibited tumor growth 
in a mouse lung cancer xenograft model.
40–43
 Leischner et al.
42
 reviewed Res to be a promising 
natural stimulant of immune responses including NK cells, CD8+ and CD4+ T-cells. 
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Mechanistic investigations revealed that Res act as a natural inhibitor for the matrix 
metalloproteinase (MMP)-7 and -9 which play a role in malignant tumor invasion, and tumor 
metastasis.
40,44
 There is conclusive evidence that the mechanism of modulation of MMP-7 and -9 
is due to the innate ability of Res to inhibit β-catenin pathway and decreased activity of signal 
transducer and activator of transcription 3 (STAT3).
45,46
 Gum Arabic (GA) a complex mixture of 
polysaccharides (galactose backbone branched with mannose, arabinose, rhamnose, α- and β-
sugar residues) and glycoproteins that are cross-linked forming arabinogalactan proteins, which 
makes up the majority of its overall structure.
47
  
The exudates of Acacia seyal trees are the source of GA and it has been used as a stabilizer in the 
food industry.
48–51
 Therefore, creation of palladium nanoparticles encapsulated with anti-tumor 
Res and GA to optimize stability presents an unprecedented opportunity to exploit the dual 
therapy effects of both the palladium nanoparticles and also the surface coated Res.
52
 There is 
also evidence that surface encapsulation of Res on nanoparticles surface would enhance their 
bioavailability and facilitate synergistic biorthogonal response in vivo.
53
 This can also be 
extended on how resveratrol-derived phenol nanoparticles can be internalized into the laminin 
receptor positive cancerous cells. Res can be used to sensitize tumor cells through an additive, 
potentiation and synergistic effects with PdNPs for a augmented therapeutic response that creates 
an optimal modality approach, which can ultimately facilitate clinical applications of 
combination regimens in the future of cancer therapy.  
2.3 Combinational treatment parameter 
It is apparent that monotherapeutic options for cancer treatment may not be able to exhibit the 
most beneficial effects, thereby a combinational treatment approach that target tumor specific 
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receptors may result in a greater therapeutic efficiency. Chiou et al.
54
 alluded that there are 
crucial principles that need to be considered when developing a combinational treatment. That is, 
neutralizing responses and overlapping unacceptable toxicity that is greater than clinical benefit. 
The use of natural product-based agents such as Res in combination with nanodrugs is a 
promising approach. Therefore, the above mentioned experimental rationale and the synergistic 
therapeutic effects of Res-derived phenols encapsulated PdNPs as drug-like metal architecture 
prompted us to hypothesize that the production of nanoparticles of palladium encapsulated 
with Res would create the next generation of cancer therapy nanomedicine agents capable of 
delivering potent doses of both resveratrol-derived phenols and polyphenols encapsulating the 
nanoparticles directly to tumor cells. Tumor selective affinity of resveratrol on the Pd surface 
would lead to endocytosis of PdNPs thus providing an additional armamentarium for therapy 
through NIR 808 nm laser induced heat production around PdNPs present within tumor cells 
providing a synergistic biorthogonal response. We further hypothesized that the mechanism of 
cell death will involve immunomodulatory characteristics because resveratrol has been known to 
induce immunomodulation by their ability to target cell signaling pathways as well as 
macrophages. The amalgamations of resveratrol conjugated palladium nanopharmaceutical could 
be a new addition to the nanomedical repertoire in the near future. 
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2.4 Aim and objectives of the study 
2.4.1 Aim  
The main goal of this research was to explore the production of biocompatible palladium 
nanoparticles using resveratrol to treat, image and evaluate the efficacy of the formulation in 
prostate cancer.  
2.4.2 Objectives  
This work was classified into three parts with the following objectives: 
1. The production and characterization of palladium nanoparticles synthesized using 
resveratrol (Res-PdNPs) for the imaging and treatment of prostate cancer.  
2. To increase the resveratrol-derived phenols and polyphenols corona loading on the 
palladium nanoparticle surface capable of providing adjuvant therapeutic benefits 
through delivering potent doses of both resveratrol and nanoparticles directly to tumor 
cells.  
3. The prostate tumor selective affinity of Res-PdNPs via endocytosis was evaluated. 
Our overarching goal for this study is to exploit the inherent anti-angiogenesis and pro-apoptotic 
properties of palladium nanoparticles through synergistic anti-tumor characteristics of 
resveratrol—all aimed at developing a new class green nanotechnology-based phytochemical 
embedded palladium nanoparticles for applications in prostate cancer therapy. 
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CHAPTER 3 
MATERIALS AND METHODS 
3.1 Materials 
All chemicals and reagents used in the synthesis of palladium nanoparticles (PdNPs) were 
purchased from standard vendors: Sodium tetrachloropalladate (II) (Na2PdCl4); resveratrol (Res), 
cisplatin and etoposide (Sigma-Aldrich, St. Louis, MO, USA) and gum arabic (GA) (Thermo 
Fisher Scientific, NJ, USA). ICP-element standard: Pd(NO3)2 (purity: 99.99 %), Media: Roswell 
Park Memorial Institute (RPMI)-1640, Hank's Balanced Salt Solution (HBSS), fetal bovine 
serum (FBS), TryplE, Trypan blue, MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium 
Bromide), DAPI (4',6-diamidino-2-phenylindole), Wheat germ agglutinin (WGA), Oregon 
Green® 488 conjugate were obtained from ThermoFisher Scientific, USA.  
3.2 Cell line used in this study 
Cell lines used in this study included prostate cancer (PC-3) cells that were obtained from the 
American Type Culture Collection (ATCC) (Manassas, VA, USA), and cultured by the 
University of Missouri Cell and Immunobiology Core facility using procedures recommended by 
ATCC. Primary human aortic endothelial cells (HAECs) were used in the study as the normal 
control cell line. The PC-3 cells were maintained in RPMI-1640 media supplemented with [+] L-
glutamine, 10 % FBS and 0.7 mL gentamicin, and HAEC cells were maintained in vascular cell 
basal medium supplemented with endothelial cell growth kit-VEGF (ATCC, Manassas, VA, 
USA). 
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3.3 Characterization of palladium nanoparticles (PdNPs) 
The absorption measurements were collected by using the Cary 60 UV-vis spectrophotometer, 
Agilent Technologies, Santa Clara, USA. A Malvern Zetasizer Nano-ZS90, Malvern Instruments 
Ltd., UK using dynamic light scattering (DLS) was used to determine the hydrodynamic size and 
zeta potential. Eppendorf 5424R centrifuge (Eppendorf AG, Hamburg, Germany) was used to 
purify the PdNPs and the concentration of Pd was measured by Inductively coupled plasma - 
optical emission Spectroscopy (ICP-OES), Perkin Elmer, MA, USA while the quantification of 
Res molecules conjugated to the surface of the PdNPs was investigated using liquid 
chromatography-tandem mass spectrometry (LC-MS/MS) with multiple reaction monitoring 
(MRM) (Thermo Fisher Scientific, Waltham, MA). Cellular viability studies were measured 
using the Molecular device SpectraMax M2 microplate reader at 570 nm, CytoViva Nanoscale 
Hyperspectral Microscopy, (CytoViva, Inc., Auburn, USA), the Leica SP8 spectral confocal 
microscope (Leica microsystems, Wetzlar, Germany) was used to investigate cellular 
internalization of the PdNPs, and Olympus 1X71 Fluorescent Microscope, (Olympus, Tokyo, 
Japan) was used to study cellular morphological changes of the cells. The acquisition of 
Transmission Electron Microscope (TEM) images was by loading the PdNPs onto a carbon-
coated copper grid (carbon square 200 mesh (CF200-CU-UL), Hatfield, PA, Electron 
microscopy sciences (EMS), USA) and the sample-loaded grid was subsequently air-dried. TEM 
images were acquired with JEOL 1400 TEM operated at 300 kV (JEOL, Ltd, Tokyo, Japan). 
Elemental studies were obtained on EI Tecnai F30 G2 Twin TEM with HAADF STEM coupled 
to an energy-dispersive X-ray spectroscopy (EDS), JEOL, LTD., Tokyo, Japan. The functional 
groups of Res conjugated to the surface of PdNPs were characterized by Fourier-transform 
infrared spectroscopy (FT-IR). The FT-IR spectra were acquired with a Varian 640-IR (Agilent 
Technologies, Santa Clara, CA, USA). 
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3.4 Synthesis of resveratrol-derived phenols encapsulated palladium nanoparticles (Res-
PdNPs) 
The synthesis of palladium nanoparticles was prepared as shown in Scheme 2. 
 
Scheme 2: Synthesis of PdNPs using resveratrol as a reducing and capping agent. RT – 
room temperature 
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3.4.1 Res initiated and stabilized palladium nanoparticles (Res-PdNP-1 and Res-PdNP-2) 
The production of Res-PdNPs (Res-PdNP-1 and Res-PdNP-2) was carried out by varying the 
amount of Res (from 0.5 to 8 mg) dissolved in 6 mL of distilled water and stirred, to this mixture 
100 µL of two concentrations of Na2PdCl4 (10 mM and 0.1 M). After completing rigorous 
extensive optimization and reproducibility studies. The following synthetic routes were 
achieved: 
Res-PdNPs were synthesized by adding 2 mg of Res into a 20 mL vial and 6 mL of distilled 
water were added. The mixture was stirred for 5 min at room temperature. To the mixture, 100 
µL of 0.1 M Na2PdCl4 salt was added for the production of Res-PdNP-1. An attempt to increase 
the Res-derived phenols and polyphenols corona on the PdNPs, 6 mg of Res was used for the 
synthesis while other reaction conditions remained consistent, for the production of Res-PdNP-2. 
The color of the solutions changed from a white to a dark brown solution, which indicated the 
formation of PdNPs and the solution was stirred overnight for optimization. The Res-PdNPs 
solutions were washed twice; by ultracentrifugation at 17000 rpm at 12 °C for 15 min using an 
Eppendorf 5424R centrifuge (Eppendorf AG, Hamburg, Germany) and re-suspended in distilled 
water.  
3.4.2 Res initiated and gum arabic stabilized palladium nanoparticles (Res-PdNP-3 and 
Res-PdNP-4 
The production of Res-PdNP-3 and Res-PdNP-4 was facilitated through the addition of different 
ratios of gum arabic (GA) to Res (0.5:1, 1:1, 1.5:1 and 2:1). The synthetic routes were optimized 
to achieve the reproducibility of Res-PdNP-3 and Res-PdNP-4. The Res-PdNPs were synthesized 
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by adding 2 mg of Res and 3 mg of GA into a 20 mL vial and 6 mL of distilled water were 
added. The mixture was stirred for 5 min at room temperature. One hundred µL of 0.1 M 
Na2PdCl4 salt was added to the mixture to produce Res-PdNP-3. On the other hand, 6 mg of Res 
was used to increase the Res-derived phenols and polyphenols corona on the PdNPs for the 
production of Res-PdNP-4. The color of the solutions changed from a white solution to a dark 
black colored solution, which indicated the formation of PdNPs and the solution was stirred 
overnight. The PdNPs solution was washed twice by ultracentrifugation at 17000 rpm at 12 °C 
for 15 min and re-suspended in distilled water.  
Control PdNPs were produced using GA: Briefly, 12 mg GA was dissolved in 6 mL of distilled 
water and stirred at 100 °C for 5 min. To this mixture, 100 µL of 0.1 M Na2PdCl4 solution was 
added for the production of gum arabic stabilized palladium nanoparticles (GA-PdNPs). 
3.5 Characterization of PdNPs 
3.5.1 In vitro stability analysis of PdNPs 
The stability of Res-PdNP-1, Res-PdNP-2, Res-PdNP-3 and Res-PdNP-4 was further confirmed 
by mixing the 1 mL of PdNPs with 2 mL of various biological solutions  in triples (n=3) such as 
aqueous solutions of 1% NaCl, 0.5% cysteine, 0.2 M histidine, 0.5%  human serum albumin 
(HSA), 0.5% bovine serum albumin (BSA), and pH 5, pH 7, pH 9 and a mixture of these 
solutions at equivalent volumes was incubated at 37 °C to mimic in vivo condition, respectively. 
The samples were measured by DLS using the Malvern Zetasizer Nano-ZS90 to monitor the 
change in the hydrodynamic size as a parameter for stability, this was measured for a week. 
91 
 
3.5.2 Determination of palladium nanoparticles concentration 
The concentration of PdNPs can be determined by calculation using a geometric method and 
experimentally using inductively coupled plasma atomic emission spectroscopy (ICP-OES). 
 
(i) Geometric methods 
The crystallization of palladium nanoparticles in each unit cell consists of 8 corners: 1/8 and 6 
faces: 1/2, therefore a unit cell has (8 x 1/8) + (6 x 1/2) = 4 atoms as shown in Scheme 3. 
 
Scheme 3: Unit cell of a face centered cubic (FCC) crystalline palladium nanoparticle 
The radius of a Pd atom can be calculated, given that Pd has an FCC crystal structure, a density 
(d) of 12.0g/cm
3
, and an atomic weight (M) of 106.4 g/mol, NA is Avogadro’s number (per mol) 
is 6.022x10
23
, Z is the number of atoms per unit cell = 4, a is the edge length and r is the atomic 
radius in Eq. 1 and 2.
211–213
 
                                                      Eq. 1 
Relation between atomic radius(r) and edge length (a) is given by: 
92 
 
 
                                                            Eq. 2 
Solve for r 
 
                                                        r
3
 = 2.59x10
-23
 
                                                        r = 1.37x10
-8
 cm 
                                                        r = 0.1375 
Since the atomic radius for Pd = 0.1375 nm, the volume (Vc) of the unit cell is calculated using 
Eq. 3, were a is the edge length      
                                                                   Vc = a
3      
 
93 
 
                                                                                                          Eq. 3 
 
                                                                      = 0.05877  
Atomic packing 
Spherical palladium nanoparticles: 
  
 
 
Atomic packing factor can be calculated using Eq. 4: 
   Eq. 4 
      
Where n – number of atoms/unit cell n = 4 
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Final derivation relies solely on the radius or diameter of the nanoparticle core using Eq. 5 to 
determine the average number of palladium atoms per nanosphere: 
N = 285.1𝑟3      Eq. 5 
Where r is the radius of the nanoparticle. To determine the concentration of PdNPs/mL, Eq. 6 
was used, where NT – total number of Pd atoms divided by N – average number of palladium 
atoms per nanosphere, where V (1 lit) is the volume of the reaction solution in liter and NA is the 
Avogadro’s constant (6.022x1023). The concentrations of nanoparticles were calculated with the 
following formula: 
                                 
            Eq. 6 
(ii) Inductively coupled plasma - optical emission spectroscopy (ICP-OES) 
Inductively Coupled Plasma - Optical Emission Spectroscopy (ICP-OES) instrument (Model: 
4100, Agilent Inc., Santa Clara, CA, USA) was used to determine the concentration of Pd in the 
PdNPs. The sample introduction system consisted of solvent-resistant tubing, a double-pass 
cyclonic chamber, and an inert flow blurring nebulizer (Nene). Acid digestion technique was 
utilized for the preparation of samples. PdNPs were digested in a mixture of HNO3 (1.1 mL ∼65 
%) and HCl (0.3 mL ∼30 %) and diluted to 10 mL with ultrapure water. Three replicates of the 
sample and a certified reference material (ICP-element standard: Pd(NO3)2 (purity: 99.99 %) 
diluted to 1 mg/mL were analyzed. Total elemental concentrations of the PdNPs were 
determined by ICP-Quadrupole-MS (ICP-QMS; Agilent 7700 series, Agilent Technologies, 
Germany). The ICP-MS was equipped with a PEEK Mira Mist nebulizer (Burgener research, 
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Canada) and a PFA inert sample introduction kit with a sapphire injector (inner diameter 2.5 
mm, for Agilent 7700 series, Agilent Technologies, Germany). Measurements were conducted at 
a RF power of 1,550 W and a carrier gas flow of 1.17–1.18 L/min. 
3.6 Quantification of resveratrol on the surface of PdNPs 
3.6.1 Liquid chromatography-tandem mass spectrometry multiple reaction monitoring 
(LC-MS/MRM) 
The amount of Res molecules conjugated to the surface of the PdNPs was quantified using liquid 
chromatography-tandem mass spectrometry (LC-MS/MS) with multiple reaction monitoring 
(MRM) on a Quantiva triple quadrupole mass spectrometer (Thermo Fisher Scientific, Waltham, 
MA). Method development was conducted to determine MRM transitions for Res and its 
retention time on the column. The Res-PdNPs were stored at 4 °C prior to analyses. The Res-
PdNPs were centrifuged at 16K x g in a micro-centrifuge tube and the supernatant diluted 
1:10,000 with internal standard solution (30 ng/mL tolbutamide in 5% acetonitrile (ACN)/1% 
formic acid (FA)). Then 25 µL was transferred into autosampler vials and placed in a cooled (7 
°C) autosampler.   
Res standard (5 µL) was full-loop injected into a C18 trap column (C18 trap, Eksigent) and the 
sample was eluted from the trap column and separated on a 20 cm x 75µm inner diameter pulled-
needle analytical column packed with HxSIL C18 reversed phase resin (Hamilton Co.) with a step 
gradient of acetonitrile at 500 nL/min. The Eksigent Nano 1D plus HPLC system is attached to a 
Thermo Scientific TSQ Quantiva triple-quadrupole mass spectrometer. LC gradient conditions: 
Initial conditions were 2% B (A: 0.1% formic acid in water, B: 99.9% acetonitrile, 0.1% formic 
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acid), followed by 2 min ramp to 90% B, held at 90% B for 8 min, ramped back to (1 min) and 
held at (2 min) initial conditions. Total run time was 10 min. 
MRM conditions: ionization voltage 1600V, Q1 & Q3 resolution 0.7 (full-width half max), 
collision gas 2.5 mTorr, Dwell Time 200 msec. An MRM transition consists of a precursor-
fragment pair, which allowed the mass spectrometer (Thermo Scientific TSQ Quantiva QQQ) to 
ignore every molecule in a sample except the Res to facilitate accurate quantitation with very 
high specificity and sensitivity. To specifically quantify the Res, two optimized transitions were 
generated as follows: The stock solution of Res (2.5 mg/mL in ethanol) was diluted 1:1000 in 
70% ACN, 0.1% FA. This solution was then analyzed by direct infusion (3 µL/min) for 
quantification.  
3.7 Cellular studies of PdNPs encapsulated with Res-derived phenols and polyphenols  
3.7.1 MTT Cell Proliferation Assay 
MTT Cell Proliferation Assay kit was obtained from ATCC, was used to determine the in vitro 
cellular viability of the Res-PdNPs against the cells (prostate cancer (PC-3) and primary aortic 
endothelial cells (HAEC) used in this study. Briefly, 100 µL/well of 5x10
4
 cells/mL were seeded 
into 96-well plates and the cells were incubated for 24 h at 37 °C in CO2 incubator with 5% CO2. 
After incubation, the media was removed and the cells were treated with the Res-PdNPs, GA-
PdNPs, free Res and GA, while cisplatin and etoposide were used as positive controls and cells 
with no treatment were used as negative controls at different concentrations (0, 2.75, 5.5, 11, 22 
and 44 µg/mL), respectively. The cells were treated at different time intervals (24, 48 and 72 h) 
and after incubation in a quadruplet manner, 10 µL of MTT dye solution was added in each well 
and the plates were incubated further for 4 h to allow crystallization. The media solution was 
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carefully removed and 100 µL of dimethyl sulfoxide (DMSO) was added to dissolve the 
formazan crystals. The cell viability was measured by microplate reader (Molecular device, 
USA) operating at 570 nm. The percent cell viability was calculated by using the formula:  
Cellular viability (%) =  
Absorbance of the treated cells at 570 nm
Absorbance of untreated cells at 570 nm
 x 100% 
The half-maximal inhibitory concentration (IC50) values were calculated using GraphPad Prism 
version 6.01 software.  
3.7.2 Migration assay 
The 6-well plates were marked to monitor the region for acquiring an image and 5x10
5
 cells/mL 
was seeded into 6-well plates and the cells were incubated for 24 h for 100 % confluence. A 200 
µL pipette tip was used to aseptically make a vertical stretch though the cell monolayer. The 
media and cell debris were carefully aspirated and the plates were gently watched once with 1x 
PBS solution. The cells were treated with highest concentration of Res-PdNP-4 (44 µg/mL) for 
24 h. The Olympus 1X71 Fluorescence Microscope (Shinjuku, Tokyo, Japan) was used to 
acquire images of the cells at 1 and 24 h after treatment. The area of the stretch was measured 
using the CellSens Dimension Software 1.13. 
3.7.3 Cellular internalization and trafficking pathway 
The cellular internalization mediated endocytosis mode of Res-PdNPs was investigated by 
blocking the laminin receptor (67LR) overexpressed onto prostate and various other tumor cells. 
The optimum dose and incubation time was determined by incubating the cells with highest 
concentration of Res-PdNP-4 (44 µg/mL) for different time points (6 and 24 h). Cell trafficking 
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pathway of Res-PdNPs was further evaluated by using RPSA Monoclonal Antibody (MLuC5) 
inhibitor to confirm laminin receptor mediated endocytosis.  
This experiment was performed by two techniques – confocal fluorescence microscope and 
TEM. For dark field and confocal microscopic studies, ultra clean and sterile cover slips were 
kept in 6 well plate to grow the cells on the cover slip. For the study by TEM technique, cells 
were grown on the plate without the coverslip. Briefly, 8x10
5
 cells/mL were seeded into 6 well 
plates in the respective media and incubated for 24 h in CO2 incubator at 37°C. The cells were 
pre-incubated with the inhibitors as following: PBS (control) and MLuC5 laminin receptor 
antibody (10 µg/mL; 60 min) and the cells were incubated in CO2 incubator at 37°C. After the 
incubation, cells are washed twice with 1x PBS followed by the treatment with Res-PdNP-4 (44 
µg/mL) for 6 h in CO2 incubator at 37°C. The samples were prepared for the following 
techniques: 
3.7.4 Confocal and dark-field microscopic technique 
After incubation, cells were washed five times with 1x PBS and fixed with 4% para-
formaldehyde (PFA) and further incubated for 15 min in the dark. The cells were washed three 
times with 1x HBSS and cells were labeled with 2 µg/mL WGA conjugate, incubated for 10 min 
at room temperature in the dark. After incubation, the cells were washed twice with 1x HBSS, 
thereafter, the cells were permeabilized with 0.2% Triton X-100 for 5 min at room temperature. 
The cells were further washed twice with 1x HBSS and the slides were prepared by using DAPI 
nuclear dye and observed with CytoViva Nanoscale Hyperspectral Microscopy coupled with 
dual mode fluorescence (CytoViva, Inc., Auburn, USA) and the Leica SP8 spectral confocal 
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microscope. Cell morphology was initially observed, followed by the uptake of Res-PdNP-4 and 
the images were captured via Dage Imaging Software and LAS X software, respectively. 
3.7.5 Transmission electron microscopy (TEM) technique 
This technique provided an overview of the Res-PdNP-4 uptake in the each cell compartment. 
After incubation, cells were washed 10 times with 1x PBS solution, centrifuged into pellets, and 
fixed with 2% glutaraldehyde 2% paraformaldehyde in sodium cacodylate buffer (0.1 M) 
incubated for 15 min in the dark. The cells were further post-fixed with 1% buffered osmium 
tetraoxide in 2-mercaptoethanol buffer and dehydrated in graded acetone series and embed in 
Epon-Spurr epoxy resin. Sections were cut at 85 nm using a diamond knife (Diatom, Hatfield 
PA, USA). The sections were stained with Sato’s triple lead stain and 5% aqueous uranyl acetate 
for organelle visualization. The prepared samples were examined on JEOL 1400 TEM 
microscope (JEOL, Peabody, Mass.) operated at 80 kV at the University of Missouri’s Electron 
Microscopy Core Facility, Columbia, MO, USA. 
3.8 Animal studies 
The in vivo experiments of Res-PdNPs involving animals were approved by the Institutional 
Animal Care and Use Committees (IACUC) of the Harry S. Truman Memorial Veterans Hospital 
and the University of Missouri-Columbia, MO, USA. The experiments were performed 
according to the guidelines outlined in the Care and Use of Laboratory Animals. Imprinting 
control regions-severe combined immunodeficiency (ICR - SCID) male mice (from Taconic 
Farms, Hudson, New York) were used for the therapeutic study. The mice used in our 
investigations weighed 28-31 g.  
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3.8.1 In vivo therapeutic efficacy study of Res-PdNP-4 
The severely compromised immunodeficiency (SCID) male mice were subcutaneously 
inoculated with 10x10
6
 prostate cancer (PC-3) cells (suspended in 0.1 mL of sterile DPBS and 
Matrigel® (2∶1, v:v)) in the right hind flank under inhalation anesthesia (isoflurane/oxygen). 
After inoculation, the animals were treated when the tumors were palpable by intravenous (IV) 
administration twice a week. The mice were randomly divided into three groups (n= 5/group) 
with no significant difference in tumor volume, the day of randomization was considered day 
zero of therapy study. At the day 0, tumors in the mice were measured by digital caliper 
measurements and calculated as length x width x height. The first group was IV injected with 
100 µL saline, this served as the control group. The second group was IV injected with 100 µL 
Res-PdNP-4 (0.25 mg/kg bw) whereas the third group was IV injected with 100 µL free Res (7 
mg/kg bw) as shown in Table 5.  
Table 5: Antitumor study dose design for the animal body weight (kg) 
Group Sample Dose (mg/kg bw) Number of mice 
1 Saline control -- 5 
2 Res-PdNP-4 IV 0.25  5 
3 Free Res 7 5 
IV
Intravenous administration 
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The animals were monitored for their tumor volume, body weight and health effects for another 
6-7 weeks and were sacrificed at the end of the study. A normal healthy group of mice (n=5) that 
had not been experimentally manipulated served as control for complete blood counts (CBC) 
parameters (mean counts for white blood cells (WBC), red blood cells (RBC) as well as 
hemoglobin, lymphocytes, and platelets counts) and body weight/eating habits of animals to 
monitor the tolerated of the treated groups. Body weight and tumor volume measurements were 
observed twice per week for all groups, for approximately 6-7 weeks. Animals were sacrificed at 
the end of study or when tumors reached endpoint (when animals were experiencing pain, 
distress and illness through the evaluation of body weight, physical appearance, measurable 
clinical signs, unprovoked behavior, response to external stimuli and a tumor burden greater than 
10% body weight. Tumors were submitted for histology for the angiogenesis measurements. For 
angiogenesis analysis, animal tissues were stained with CD31 antibody.  
3.9 Statistical analysis 
All experimental data were given as mean±SEM. Statistical analysis was carried out using the 
one-way analysis of variances (ANOVA) using Graph Pad Prism software. P<0.05 was 
considered significant.  
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CHAPTER 4 
RESULTS AND DISCUSSIONS  
4.1 UV-Vis spectroscopy of palladium nanoparticles (PdNPs) encapsulated with resveratrol 
(Res)-derived phenols and polyphenols   
4.1.1 Res initiated and stabilized palladium nanoparticles (Res-PdNP-1 and Res-PdNP-2) 
Resveratrol was utilized to produce palladium nanoparticles. Res-derived phenols and 
polyphenols encapsulated palladium nanoparticles were synthesized through a redox reaction by 
transferring electrons from hydroxyl groups of Res to the palladium salt. The formation of 
PdNPs was observed by a color-change from a colorless solution to a brown color solution. The 
chemical structure of the Res plays a significant role as a powerful electron injector that also 
creates coating on palladium nanoparticles surface. The resulting solution of nanoparticles (Res-
PdNP-1 and Res-PdNP-2 (increased Res-derived phenols and polyphenols corona)) was 
characterized by measuring the morphology, size distribution and surface charge determined by 
ultraviolet-visible (UV-Vis) spectroscopy, transmission electron microscopy (TEM) and 
dynamic light scattering (DLS), respectively.  
The UV-vis spectra of Res showed an absorption peak at 306 nm, representing trans-
resveratrol.
1–3
 The UV -vis spectra of the metal precursor (Na2PdCl4) has an absorption peak at 
420 nm attributed by Pd
2+
 ions.
4,5
 The UV-Vis spectra of the Res-PdNP-1 and Res-PdNP-2 
solution revealed the disappearance of 420 nm absorbance, which confirmed the reduction of the 
Pd
2+
 to Pd
0
, thereby confirming the synthesis of PdNPs (Figure 13).  
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Figure 13: UV-Vis spectra of palladium nanoparticles encapsulated with resveratrol-
derived phenols and polyphenols a) free Res, GA and Res-GA mixture, b) Res-PdNP-1 and 
Res-PdNP-2 and c) Res-PdNP-3 and Res-PdNP-4. 
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4.1.2 Res initiated and Gum Arabic stabilized palladium nanoparticles (Res-PdNP-3 and 
Res-PdNP-4)  
The color-change from a colorless solution to a dark-brown color solution and the disappearance 
of the 420 nm peak on the UV-Vis spectra of GA stabilized PdNPs revealed the successful 
production of PdNPs.
6
 The absorption peak at 306 nm of the Res-PdNP-3 and Res-PdNP-4 
(increased Res corona) indicated Res-derived phenols and polyphenols encapsulation on the 
surface of the PdNPs. The intensity of the Res peak was higher in Res-PdNP-4 as compared to 
Res-PdNP-3 which was due to increased Res-derived phenols and polyphenols corona on the 
surface of the PdNPs as shown in Figure 13. Moreover, The UV-Vis spectra of the Res-GA 
mixture (Figure 13) predominantly showed the 306 nm absorption peak reflected by Res 
molecule anchoring onto the structure of GA. This data revealed that GA provides a supportive 
matrix to stabilize nanoparticles and increase the loading of Res-derived phenols and 
polyphenolic molecules.
7
  
The physicochemical properties of the synthesized PdNPs were further evaluated by dynamic 
light scattering (DLS) and transmission electron microscopy (TEM). The DLS was used to 
determine the hydrodynamic size and zeta (ζ) potential of Res-PdNPs. The DLS measurements 
revealed that the hydrodynamic sizes of Res-PdNP-1, Res-PdNP-2, Res-PdNP-3 and Res-PdNP-
4 were 93±4, 254±18, 44±1, and 117±4 nm, respectively, as shown in Table 6. It was expected 
that Res-PdNP-2 and Res-PdNP-4 would have a significantly larger hydrodynamic size 
compared to Res-PdNP-1 and Res-PdNP-3 due to increased Res-derived phenols and 
polyphenols corona on the surface of the PdNPs due to the surface coating (Table 6).
7–9
 The ζ-
potential provides crucial information of inter-particle and nanoparticle-cell interaction on the 
stability of nanoparticles in solution. The magnitude of the ζ-potential (hydrodynamic shear 
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force) indicates the degree of electrostatic repulsive forces between adjacent particles in fluid 
environment of the blood resulting in low serum protein binding and potentially longer 
circulation time.
10
  This provides an excellent index for the efficient dispersion and the long-term 
stability for both in vitro and in vivo systems for the application of PdNPs in biomedical and 
other applications. 
The ζ-potentials were -26±2, -28±3, -31±1 and -40±3 mV for Res-PdNP-1, Res-PdNP-2, Res-
PdNP-3 and Res-PdNP-4, respectively (Table 6). A higher ζ-potential is directly proportional to 
the stability of the nanoparticles, indicating no tendency of the particles to aggregate.
11
 The 
anionic carboxyl groups of GA offer additional stability as shown by a higher ζ-potential 
compared to Res-PdNPs without GA.
12
  The polydispersity index (PDI) indicates the quality of 
the nanoparticles with respect to the average uniformity (shape and size) of a particle solution, 
whether the nanoparticles are monodispersed or polydispersed on the basis of size distribution, 
which is a highly important physical characteristic of pharmaceutical-grade products.
13
 The 
FDA’s Guidance for Industry emphasizes the importance of particle size distribution 
(polydispersity) as nanomaterial’s critical quality attributes (CQAs).13 According to Danaei et 
al.
13
 in drug delivery applications using lipid-based carriers (liposome and nanoliposome 
formulations, such as Doxil®, Abraxane®, NanoTherm®,Ferumoxtran-10, and CellSearch®), 
PDI values that are less than 0.3 are acceptable for clinical applications. The PDI of the 
synthesized PdNPs indicated that Res-PdNP-1, Res-PdNP-3 and Re-PdNP-4 was 0.3, which 
indicate monodispersity; the PDI of Res-PdNP-2 was at 0.5 reflecting some degree of 
polydispersity as shown in Table 6.  
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4.2 Electron microscopy studies of Res-PdNPs 
The TEM images revealed that Res-PdNPs were monodispersed and are spherical in shape as 
shown in Figure 14. The size distribution for the measurement of the core size was performed by 
the analysis of the TEM images using the ImageJ software, and showed that the average core 
sizes of Res-PdNP-1, Res-PdNP-2, Res-PdNP-3 and Res-PdNP-4 are 83±14, 53±14, 24±6 and 
9±3 nm, respectively (Figure 14 and 15). For the Res-PdNPs with GA (Res-PdNP-3 and Res-
PdNP-4), one would expect a higher size, however the arabinogalactan proteins of GA have been 
reported as reducing and stabilizing agents for the synthesis of nanoparticles.
14
 Similarly 
Moreno-Trejo and Sánchez-Domínguez
14
, reported on the use of Mesquite Gum (proteinaceous 
arabinogalactan gum that is similar to GA) as a reducing and stabilizing agent for the synthesis 
of highly concentrated silver nanoparticles. Moreover, these proteins give some physicochemical 
properties (immunochemical identity and high solubility in water) to the GA to form compact 
coacervation of globular structures; these structures in aqueous solution provide the capacity to 
reduce the surface tension and to act as a steric stabilizer.
15
 The TEM image of Res-PdNP-2 
shows that the nanoparticles seem to be denser compared to the Res-PdNP-1, and this can be 
attributed to amount of loaded Res-derived phenols and polyphenolic molecules as concurred 
with the DLS data.  
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Figure 14: TEM image and size distribution of a) Res-PdNP-1 and b) Res-PdNP-2. 
a) Average size: 83±14 nm 
b) Average size: 53±14 nm 
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Figure 15: TEM image and size distribution of a) Res-PdNP-3 and b) Res-PdNP-4. 
It is to be expected that the hydrodynamic sizes of PdNPs are significantly greater than the core 
sizes, confirming surface coating – that is Res-derived phenols and polyphenolic molecules have 
been encapsulated onto the surface of the palladium nanoparticles rendering them optimum in 
vitro and in vivo stabilities. Moreover, the surface coating of Res-PdNP-2 and Res-PdNP-4 is 
higher that Res-PdNP-1 and Res-PdNP-3 as a result of increased Res-derived phenols and 
polyphenols corona as shown in Table 6. Inductively coupled plasma - optical emission 
Average size:  9±3 nm 
Average size: 24±6 nm a) 
b) 
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spectrometry (ICP-OES) was performed to estimate the palladium concentration in the Res-
PdNPs (Table 6). 
Table 6: Physiochemical properties of Res-PdNPs 
Sample 
Hydrodynamic 
size (nm) 
Core size 
(nm) 
Surface 
coating 
(nm) 
PDI 
Zeta 
(mV) 
[Pd] 
(µg/mL)
a
 
Res-PdNP-1 93±4 83±14 10 0.3 -26±2 165 
Res-PdNP-2 254±18 53±14 201 0.5 -28±3 166 
Res-PdNP-3 44±1 24±6 21 0.3 -31±1 167 
Res-PdNP-4 117±4 9±3 108 0.3 -40±3 167 
a
ICP-OES, Geometric calculations revealed that [Pd] was expected at 177 µg/mL 
High-resolution TEM (HRTEM) analysis was performed to investigate crystallization, lattice 
planes and palladium atomic packing of the Res-PdNPs. The HRTEM images revealed that Res-
PdNP-1 and Res-PdNP-2 are amorphous nanoparticles that serve as intermediates for the 
generation of crystalline Pd nanoparticles; this was evident based on the results reported by 
Tianou et al.
16
 Moreover, the nucleation and crystallization of nanoparticles proceeds by two 
fundamental pathways i) aggregation of the Pd nanoclusters into larger assemblies formed by 
numerous nanoclusters (0.5 to 3 nm) and ii) structural rearrangement with pre-nucleation Pd 
nanoclusters towards direct conversion to crystalline nanoparticles as shown in Figure 16.
17
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Figure 16: HRTEM images of a) Res-PdNP-1, b) Res-PdNP-2 confirming the existence of 
individual Pd nanoclusters and c) schematic drawing visualizing Pd nanocluster 
agglomeration (structures are not drawn to scale).  
c) 
a) 
b) 
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The addition of GA allowed for the production of thermodynamically stable nanoparticles 
through kinetically inhibiting the rate of nucleation via direct crystallization. This resulted in 
particles with a higher stability; furthermore, the HRTEM images of Res-PdNP-3 and Res-
PdNP-4 revealed that the nanoparticles are crystalline with interplanar lattice d-spacing of 0.2 
nm between the lattice planes (Figure 17).
14
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Figure 17: HRTEM images of a) Res-PdNP-3, b) Res-PdNP-4 crystalline nature and c) 
Schematic drawing visualizing PdNPs nanocrystals (structures are not drawn to scale). 
c) 
b) 
a) 
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The effect of GA is to facilitate the interface transition from an amorphous to a crystalline 
resveratrol conjugated PdNPs.
18
 Thanh et al.
19
 demonstrated the nucleation and growth of 
nanoparticles in solution. They reported that during nucleation growth, small nanoparticulates 
coalescence through surface and strain energies (energy stored in a system that allows for atomic 
rearrangement) leading to the formation of an interface. These energies of interface between the 
crystalline nucleus of the small Pd nanoparticulates and the amorphous PdNPs intermediates will 
be larger than the activation energy, thereby allowing atomic rearrangements triggered by the 
non-Newtonian shear-thinning behavior of GA in solution to propagate crystallization waves 
through anchoring and compacting the amorphous nanoparticles, leading to mono- or 
polycrystalline face-centered cubic (FCC) structures.
18,20–22
 Figure 18 shows a schematic 
illustration of a crystallization mechanism of amorphous-crystalline interface of PdNPs, 
crystallization is driven by long-range elastic interaction due to small crystal nucleus formation 
in amorphous nanoparticles is induced by short-range atomic rearrangements.
23
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Figure 18: Crystal growth of palladium nanoparticles influenced by GA, and a schematic 
illustration of crystallization mechanism of amorphous palladium nanoparticles.
19
 
4.3 Elemental analysis of Res-PdNPs 
The scanning transmission electron microscope (STEM)-high-angle annular dark-field (HAADF) 
imaging and energy-dispersive X-ray spectroscopy (EDS) mapping allowed for further 
confirmation for the presence of elemental Pd. All the Res-PdNPs samples showed the presence 
of Pd as shown in Figure 19A and 19B. The presence of Cu peaks is from the Cu grid and the Na 
and Cl are by-products from the reaction during the synthesis of Res-PdNPs.  
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Figure 19A: STEM-HAADF image and EDS elemental maps showing the presence of Pd, 
O, Cu, Na and Cl in a) Res-PdNP-1, b) Res-PdNP-2, respectively and c) EDS spectrum of 
Res-PdNP-2. 
The EDS mapping of Res-PdNP-4 revealed a spatial distribution of Pd as shown in Figure 19B, 
that further corroborates the anchoring and compacting capacity of PdNPs facilitated by GA 
supportive matrix. 
a) b) 
c) 
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Figure 19B: STEM-HAADF image and EDS elemental maps showing the presence of Pd, 
O, Cu, Si, Na and Cl in a) Res-PdNP-3, b) Res-PdNP-4 and c) EDS spectrum of Res-PdNP-
4. 
4.4 In vitro stability of palladium nanoparticles 
The stability of the Res-PdNPs was evaluated by monitoring the size of the nanoparticles in 
various biological media (1% NaCl, 0.5% cysteine, 0.2 M histidine, 0.5% human serum albumin 
(HSA), 0.5% bovine serum albumin (BSA), and pH 5, pH 7, and pH 9 at 37 °C) in triples (n=3). 
Moreover, the Res-PdNPs size was also monitored in a mixture of the above-mentioned 
biological media at 37 °C to mimic in vivo conditions for a week. The results showed that the 
a) b) 
c) 
d) 
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size of the Res-PdNP-1 and Res-PdNP-2 were not stable in bovine serum albumin (BSA), human 
serum albumin (HSA), and the mixture solution. The Res-PdNP-3 and Res-PdNP-4 exhibited 
increased stability with no tendency to aggregate, thereby demonstrating superior in vitro 
stability in the tested biological fluids. This was attributed to the presence of GA, which confers 
high cohesive and adhesive properties towards improved stability of Res-PdNPs (Figure 20).
24
 
Several studies by Gamal-Eldeen et al.
25,26
, Fent et al.
27
 de Barros et al.
28
, Wu et al.
29
, Williams 
et al.
30
 demonstrated that the addition of GA promoted colloidal stabilization, which was 
primarily attributed to the existence of steric forces from the GA that prevents the aggregation of 
nanoparticles. Based on the stability, only Res-PdNP-3 and Res-PdNP-4 were investigated 
further due to their superior stability. 
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Figure 20: In vitro stability assay of Res-PdNPs by monitoring the hydrodynamic size of a) 
Res-PdNP-1 and Res-PdNP-2 and b) Res-PdNP-3 and Res-PdNP-4 in various biological 
media at 37 °C for a week (n=3). Res-PdNP-1 and Res-PdNP-2 not stable in media (green 
arrow) 
a) 
b) 
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4.5 Fourier transform-infrared (FTIR) of Res-PdNP-3 and Res-PdNP-4  
The functional group conjugation of Res-derived phenols and polyphenols on the surface of 
PdNPs was investigated by FTIR spectroscopy. An intensive wide band emerged in the range 
3363-3388 cm
-1
, attributed to the presence of phenolic hydroxyl groups (O-H stretching) of Res, 
the broad range is due to the formation of extensive hydrogen bonding among polyphenolic 
molecules in solution.
31
 The band at 2114-2150 cm
-1
 is attributed to the -C≡C- stretching 
vibrations, which can be attributed to the oxidative products of Res (triple-bond resveratrol 
analog) and the  peak at 1641-1645 cm
−1
 was attributed to the stretching vibration of –C=C- 
between the aromatic rings. The bands at 951-982 cm
-1
 were attributed to the in-plane bending 
vibration of =C-H in the aromatic ring, however this band shifted to 890 cm
-1
 reflecting out-of-
plane bending of the exomethylene groups in Res-PdNP-3. The peak at 573-640 cm
-1
 of free Res 
and Res-PdNP-4 is from monosubstitution (phenol) C-H bends. These results indicate that Res 
molecules were conjugated to the Res-PdNPs surface with high affinity for the metal center and 
generally does not dissociate under physiological conditions as indicated by high stability 
(Figure 21).  
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Figure 21: Fourier transform-infrared (FTIR) spectra of free Res and Res-PdNPs.  
4.6 Quantification of Res-derived phenols and polyphenolic molecules encapsulated onto 
the surface of the nanoparticles by liquid chromatography-tandem mass spectrometry with 
multiple reaction monitoring (LC-MS/MRM) 
The concentration of Res-derived phenols and polyphenolic molecules encapsulated on the 
surface of Res-PdNP-3 and Res-PdNP-4 was determined to be 6 and 20 µg/mL, respectively as 
quantified using LC-MS/MS with multiple reaction monitoring (MRM) on the Quantiva (Figure 
22). Res-PdNP-3 significantly had lower Res compared to free Res because some of the Res 
were oxidized in the reaction for the reduction of Pd
(II)
 ions to produce Res-PdNPs and 
subsequently capping the nanoparticles. On the other hand, Res-PdNP-4 had a higher 
concentration of loaded Res-derived phenols and polyphenols attributed to the increased Res-
derived phenols and polyphenols corona on the Re-PdNP-4, thereby corroborating with the data 
obtained from DLS.  
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Figure 22: LC-MS/MRM Quantitation of Res a) Res standard curve normalized to AUC 
for tolbutamide internal standard and b) Res-PdNPs monitored by MRM to specifically 
quantify the resveratrol in the samples. 
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4.7 
1
H nuclear magnetic resonance (NMR) analysis of the Res-PdNP-4 
The presence of Res-derived phenols and polyphenols encapsulated on the Res-PdNP-4 was 
investigated by 
1
H NMR. Figure 23 shows the 
1
H NMR spectrum Res, GA and Res-GA mixture. 
The characteristic peaks of Res are seen in the region between chemical shifts (δ) 6 – 8 ppm and 
the crowded signals between δ 3 – 5.5 ppm, which are characteristic signals of polysaccharides 
(OH and CH group of mannose (δ 3.65 – 3.60 ppm), CH2 group of arabinose (δ 3.81 – 3.55 
ppm), C4 of galactose (δ 3.98, 4.28 ppm), β-sugar residues (δ 4.92 – 4.96 ppm) and α-sugar 
residues(δ 5.1 – 5.3 ppm)), while the upfield peak at 1.4 ppm is assigned to the methyl group of 
the rhamnose sugar of GA (Figure 23a and b, respectively).
32–38
 The 
1
H NMR spectrum of the 
Res-GA mixture was collected, as shown in Figure 23c, and revealed that the Res spectra does 
not overlap the GA spectra, thus allowing clear distinction and identification.  
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Figure 23: 
1
H NMR spectra of a) Free Res, b) GA and c) Res-GA mixture in D2O. 
The 
1
H NMR spectra of Res-PdNP-4 was different to the spectra of Res-GA mixture as shown in 
Figure 24. The intensity of the peaks corresponding to Res is less and significantly different in 
the Res-PdNP-4 compared to that observed in the spectrum of free Res. Notably, this further 
corroborates that Pd(II) was reduced to PdNPs via the oxidation of Res, while GA shows slight 
changes but mostly looks the same.
39
 Figure 24 insert had high signal to noise with limited 
integration details obtained. Hence understanding the oxidation product is tricky. This result 
reveals the presence of Res-derived phenols and polyphenols due to the oxidation of Res. The 
GA shows slight changes but mostly looks the same to me.   
a) 
b) 
c) 
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Figure 24: 
1
H NMR spectra of Res-PdNP-4 in D2O (insert: magnified Res region).  
A study by Camont et al.
40
 reported that ~85% of oxidization end-products of trans-Res are 
piceatannol and 3,5-dihydroxybenzoic acid, while ~15% is attributed to 3,5-
dihydroxybenzaldehyde and para-hydroxybenzaldehyde. The structure of these oxidation end-
products of trans-Res are listed in Figure 25. 
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Figure 25: Chemical structure of resveratrol (a) and of its oxidation products piceatannol 
(b), 3,5-dihydroxybenzoic acid (c), 3,5-dihydroxybenzaldehyde (d) and para-
hydroxybenzaldehyde (e). 
40
  
There are several mechanisms that can explain the 
1
H NMR spectra during the synthesis of 
PdNPs using Res. The reduction reaction follows an electron transfer mechanism that involves 
the release of both electrons and protons from the Res molecule.
41
 Based on the quantum 
chemistry calculations by the Functional of Density Theory method for the determination of 
antioxidant pharmacophore of Res. Res contains both resorcinol and phenol moieties and the B 
ring of resveratrol is more easily oxidized compared to the resorcinol ring A due to its lower 
ionization potential.
41-43
 During the production of Res-PdNPs, Pd
2+
 is reduced to Pd
0
 by an 
electron transfer facilitated by Res chelating complex with Pd
2+
 ion resulting in Res oxidizing to 
quinone which can be expressed stoichiometrically as Eq. 7 and Figure 26: 
                                   nPd
2+
 + 2R–(OH)n → nPd0 + 2nR=O + 2nH+                                       Eq. 7 
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Where R and n represent the heterocyclic or alkyl groups and the number of the hydroxyl groups 
oxidised by Pd(II) species, respectively.
41
 Bao and Liu
44
 and Keylor et al.
45
 reported of the 
chemistry and biology of various derivatives based on Res. 
 
Figure 26: Mechanism for the formation of Res-PdNPs by using Res a) simplified 
mechanism of Res to quinone form with the reduction of Pd
2+
 to Pd
0
 by electron transfer 
and b) multiple oxidative products of Res. 
Here there is oxidation at only one site, C-H changing to C-OH, change in carbon oxidation state 
is -1 to +1. A 2 electron change. Correspondingly the Pd
2+
 goes to Pd
0
, also a 2 electron 
reduction. The ratio of moles of resveratrol: Pd
2+
 is 1:1. For the Res-PdNPs: Total grams of 
resveratrol used is 0.33 mg/mL for 6 mL which is a total of 0.00198 g of resveratrol, therefore, 
a) 
b) 
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total moles of resveratrol used is 0.00198 g/228.25 g/mol = 9x10
-6
 moles and total amount of 
Na2PdCl4 used is 100 µL (1x10
-4
 L) of 0.1 M. Hence moles of Na2PdCl4 or Pd
2+
 is 1x10
-4
 L x 0.1 
M = 1x10
-5
 moles. The moles of resveratrol (9x10
-6
 moles) and Pd
2+
 (1x10
-5
 moles) is close to 
1:1, based on this most of Res is oxidized. This represents similar work by Palliyarayil et al.
41
 
reporting that the formation of PdNPs follows a 1:1 reaction using (+)-Catechin as a reducing 
agent. 
4.8 Cellular internalization study 
The cellular internalization of Res-PdNP-4 was investigated against prostate cancer (PC-3) cells 
at 42 µg/mL. The PC-3 cells were incubated with Res-PdNP-4 for 2, 6 and 24 h to be evaluated 
using dark field optical microcopy (CytoViva). The CytoViva images revealed that cellular 
internalization of Res-PdNP-4 is time-dependent with optimal uptake achieved at 24 h incubation 
(Figure 27).
46
 The CytoViva images are limited to a two-dimensional field-of-view, with a level 
of uncertainly whether the Re-PdNP-4 nanoparticles are on the surface of the cells or they are 
indeed internalized into the cell. The images in Figure 27 show that the Res-PdNP-4 are 
contained within the cytoplasm and localized around the nucleus (DAPI stained – blue).47,48  
Confocal microscopy was used to acquire a three-dimensional field-of-view. A 3D projection 
snapchat image revealed that the Res-PdNP-4 was localized inside the cytoplasm as shown in 
Figure 28. The CytoViva and confocal microscopy images of the Res-PdNP-4 seem to be 
aggregated in the cytoplasm; however, that was due to lower magnification. Thus, TEM was 
used to further investigate the integrity of the Res-PdNP-4 inside the cell. TEM image analysis of 
PC-3 cells unambiguously confirmed the internalization and localization of Res-PdNP-4 within 
PC-3 cancer cells. Moreover, the early endocytic pathway reveals the presence of pseudopodium 
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for the internalization of Res-PdNP-4.
49
 These results are in accordance with previous studies in 
that the Res-PdNP-4 were mostly encapsulated in the autophagosome-like vesicles in the 
cytoplasm (Figures 29 and 30).
48,50,51
 The trajectory of the Res-PdNP-4’s ability to escape the 
endosomal pathways within the PC-3 cells guarantees a successful delivery of Res-derived 
phenols and polyphenols encapsulated on the surface of the PdNPs nanocarrier platform.
51
  
 
Figure 27: Dark field CytoViva images of prostate cancer (PC-3) cells showing cellular 
internalization post treatment a) control (no treatment), b) PC-3 cells incubated for 2 h, c) 
PC-3 cells incubated for 6 h and d) PC-3 cells incubated with 42 µg/mL Res-PdNP-4 for 24 
h. 
b) a) 
c) d) 
Nucleus  
Nucleus  
Nucleus  
Nucleus  
Cytoplasm  
Cytoplasm  
Cytoplasm  
Cytoplasm  
Res-PdNP-4 
Res-PdNP-4 
Res-PdNP-4 
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Figure 28: Confocal microscopy images of a) PC-3 control cells (no treatment) and b) 3D 
projection of a), c) PC-3 cells incubated with 42 µg/mL Res-PdNP-4 for 6 h and d) 3D 
projection of c). Nucleus (DAPI stain – blue), cytoplasm (WGA stain – green) and Res-
PdNP-4 (yellow). 
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Figure 29: TEM images indicating cellular internalization of Res-PdNP-4 at 6 h post 
treatment a) PC-3 control cells (no treatment), b) PC-3 cells treated with 42 µg/mL Res-
PdNP-4, c) magnified image of b) and d) size distribution histogram of Res-PdNP-4. 
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Figure 30: TEM images indicating cellular internalization through endocytic pathway. 42 
µg/mL Res-PdNP-4 at 6 h post treatment in PC-3 cancer cells. 
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4.9 Receptor mediated cellular internalization of Res-PdNP-4 
The CytoViva, confocal microscopy and TEM images clearly demonstrate that Res-PdNP-4 are 
internalized into prostate cancer cells with high stability and maintain their integrity inside the 
cells with no tendency to aggregate inside the cell confirming in vitro and in vivo stability. The 
mode of internalization was not confirmed at this point, however TEM images confirmed an 
endocytic pathway based on the formation of an autophagosome-like vacuole containing Res-
PdNP-4 inside the cytoplasm as shown in Figures 29 and 30. This prompted further investigation 
whether Res-PdNP-4 cellular internalization is receptor-mediated. The images obtained were 
comparable with previously reported images in the literature.
46–49,51–55
  
Res-PdNP-4 targeting capabilities were investigated towards the laminin receptors (Lam 67R), 
which are over expressed on human prostate cancer cells and breast and colon cancer.
47,56–57
 
Studies by Shukla  et al.
47
 and Khoobchandani et al.
48
 revealed that Epigallocatechin gallate 
(EGCG) conjugated gold nanoparticles (EGCG-AuNPs) demonstrated receptor-mediated 
internalization through the Lam 67R receptor in prostate cancer cells. Most recently, work by 
Diaz-Quiñone et al.
56
 reported that compounds against laminin receptor exhibit anti-cancer 
properties in prostate cancer cells. Therefore, we hypothesized that Res-PdNP-4 internalization 
in prostate cancer (PC-3) cells through endocytosis as shown by the TEM images would be 
mediated through Lam 67R receptor expression.   
Blocking studies were performed by confocal microscopy using MLuC5 antibody as a probe. 
The prostate cancer (PC-3) cells were incubated with MLuC5 to block Lam 67R receptors and 
the cells were treated with Res-PdNP-4. Confocal images revealed that Res-PdNP-4 were not 
internalized in the PC-3, which demonstrates that Res-PdNP-4 have Lam 67R receptor affinity 
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(Figure 31), thus validating the hypothesis of prostate tumor specific receptor-mediated 
internalization. Scanning tunnelling electron microscopy (STEM) and energy-dispersive X-ray 
spectroscopy (EDS) mapping was performed on the Res-PdNP-4 internalized in the prostate 
cancer (PC-3) cells, confirming that the internalized nanoparticles are indeed Res-PdNP-4 as 
shown in Figure 32.  
  
Figure 31: Confocal microscopic images showing immunocytochemical localization of Lam 
67R a) prostate cancer (PC-3) control cells (no treatment) and b) inhibition in Res-PdNP-4 
uptake in the presence of Laminin 67 receptor blocking antibody (MLuC5) at 6 h post 
treatment in PC-3 cancer cells. 
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Figure 32: STEM and EDS mapping of prostate cancer (PC-3) cells treated with 42 µg/mL 
Res-PdNP-4 a) dark-field image of PC-3 cells; b) magnified image of a) showing a vaculoe 
with nanoparticles; c) EDS mapping of Res-PdNP-4 and d) EDS spectrum confirming the 
presence of Pd inside the prostate cancer cells. 
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4.10 Assessment of the cytotoxicity of Res-PdNP-4 against prostate cancer (PC-3) cells and 
normal human aortic endothelial cells (HAEC)  
The cytotoxicity of Res-PdNP-4 was studied on prostate cancer (PC-3) cells as well as on human 
aortic endothelial cells (HAEC) to investigate the biocompatibility of Res-PdNP-4 via in vitro 
assay using colorimetric cell viability (MTT) assay. In principle, viable cells are capable of 
metabolizing the tetrazolium dye MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide to its insoluble formazan, which has a purple color. The experiment was performed by 
the treating PC-3 and HAEC cells with Res-PdNP-4 concentrations (0, 2.75, 5.5, 11, 22 and 44 
µg/mL). Alongside the treatment with Res-PdNP-4, the cells were also treated with free Res and 
GA, cisplatin (Pt-based chemotherapeutic drug), etoposide (plant-derived chemotherapeutic 
drug) and GA-PdNPs as controls. The cellular viability of prostate cancer (PC-3) against Res-
PdNP-4 after 72 h of post treatment demonstrated that Res-PdNP-4 exhibit comparable 
anticancer efficacy as cisplatin and etoposide (Figure 33) with the half maximal inhibitory 
concentrations (IC50) data summarized in Table 7. Please refer to the appendix (Figures 41 and 
42) for the results of the cellular viability of PC-3 cells at 24 and 48 h post treatments.  
 
The free GA and GA-PdNPs had no effect on the PC-3 cells in all time-points, this was because 
GA is non-toxic as reported in literature.
58,59
 Moreover, recent studies showed that GA has the 
ability to prevent the toxicity of potent chemotherapeutic drugs such as cisplatin, 
cyclophosphamide and doxorubicin.
60
 Kannan et al.
61
 and Axiak-Bechtel et al.
62
 reported that 
GA provides a nontoxic coating that prevents nanoparticle aggregation in vivo. A number of Pd 
complexes and compounds [Pd(I) and Pd(II)] have been reported to be toxic.
63–65
 However, in 
the current study, GA-PdNPs were not toxic, this could be attributed to inert Pd (0 oxidation 
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state). This suggests that the increased Res corona on the Res-PdNP-4 has a synergistic effect 
facilitated by PdNPs being effective carriers to enhance the bioavailability of Res, validating the 
therapeutic potential of Res-PdNP-4 for treating prostate cancer through adjuvant therapeutic 
benefits of inherent anti-angiogenesis and pro-apoptotic properties of PdNPs and anti-tumor 
characteristics of Res – providing an additional armamentarium in tumor therapy. 
 
Figure 33: Cell viability of prostate cancer (PC-3) after 72 h post incubation with Res-
PdNP-4 and controls (free Res, GA, GA-PdNPs, cisplatin and etoposide), n=4; results 
reported as mean±SEM.  
Based on the exceptional cytotoxic data of Res-PdNP-4 against prostate cancer (PC-3) cells, the 
Res-PdNP-4 nanoparticles were further investigated against normal human aortic endothelial 
cells (HAEC). From the cellular internalization studies by confocal microscopy and TEM 
revealed that Res-PdNP-4 has Lam 67R receptor affinity, which are receptors overexpressed in 
prostate cancer than normal cells. The HAEC cells were incubated with Res-PdNP-4, cisplatin 
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and etoposide at different concentrations (0, 2.75, 5.5, 11, 22 and 44 µg/mL) for 72 h post 
treatments. As expected, cisplatin and etoposide treatments were highly toxic to HAEC due to 
the toxicity profile while Res-PdNP-4 presented no toxicity further corroborating Lam 67R 
receptor-mediated delivery, making them specific to cancerous cells as shown in Figure 34. 
Please refer to the appendix (Figure 42) for the results of the cellular viability HAEC cells at 24 
and 48 h post treatments. 
  
Figure 34: Cell viability of normal human aortic endothelial cells (HAEC) after 72 h post 
incubation with Res-PdNP-4 and controls (cisplatin and etoposide). At high Res-PdNP-4 
concentration no toxicity was observed (green arrow) n=4; results reported as mean±SEM. 
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Table 7: in vitro cellular viability studies  
Sample Cell line 
IC50 (µg/mL) 
24 h 48 h 72 h 
Cisplatin 
Prostate cancer (PC-3) 
2 2 2 
Etoposide N/A 5 3 
Res-PdNP-4 10 7 5 
     
Cisplatin 
Normal human aortic 
endothelial cells (HAEC) 
3 2 2 
Etoposide 2 3 3 
Res-PdNP-4 15 N/A N/A 
IC
50half maximal inhibitory concentration, 
N/A
no 50% inhibition 
4.11 Cellular morphology and migration studies 
The cellular morphology of prostate cancer (PC-3) cells and normal human aortic endothelial 
cells (HAEC) was investigated. The PC-3 cells treated with Res-PdNP-4, cisplatin and etoposide 
incubated for 72 h post treatment at 42 µg/mL showed dramatic morphological changes, which is 
an initial indication of the PC-3 cells undergoing apoptosis. This was evident due to the presence 
cell shrinkage and cell debris confirming morphological characteristics of apoptosis (Figure 35). 
The treatment of HAEC cells with Res-PdNP-4 was identical to the control (no treatment) which 
revealed that Res-PdNP-4 present no toxic effect towards normal cells; however, that is not true 
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for cisplatin and etoposide since they are highly toxic towards normal cells (Figure 36). This data 
is in total agreement with the in vitro cellular viability results. This data is very convincing that 
Res-PdNP-4 is comparable to data as observed with cisplatin and etoposide in PC-3 cells. 
However, Res-PdNP-4’s low toxicity towards normal cells makes it an ideal cancer therapy.  
 
Figure 35: Cellular morphological studies of prostate cancer (PC-3) cells after 72 h post 
incubation with a) control (no treatment), b) cisplatin, c) etoposide and d) Res-PdNP-4 for 
72 h at 42 µg/mL.  
c) 
a) b) 
d) 
Cell shrinkage 
Cell shrinkage 
Cell shrinkage 
Cell debris 
Cell debris 
Cell debris 
140 
 
 
Figure 36: Cellular morphological studies of normal human aortic endothelial cells 
(HAEC) after 72 h post incubation with a) control (no treatment), b) cisplatin, c) etoposide 
and d) Res-PdNP-4 for 72 h at 42 µg/mL.  
Cellular migration studies of prostate cancer (PC-3) treated with Res-PdNP-4 revealed that the 
Res-PdNP-4 have the ability to stop cellular migration and provides preliminary evidence of 
Res-PdNP-4 to limit tumor metastasis (Figure 37). 
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Figure 37: Cellular migration study of prostate cancer (PC-3) cells treated with Res-PdNP-
4 compared with control cells (no treatment). 
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4.12 Therapeutic efficacy study of Res-PdNP-4  
The therapeutic efficacy study of Res-PdNP-4 (increased Res corona with GA) was investigated 
using human prostate tumor-bearing severely combined immunodeficient (SCID) male mice as 
the animal model to evaluate Res-PdNP-4’s ability to control or reduce tumor size. There were 
three groups of mice (n= 5) bearing prostate (PC-3) tumors with comparable size (the mean 
tumor volume ranging from 0.02-0.1 cm
3
) and mean body weights (bw) ranged from 28-31.2 g. 
After inoculation, the animals were treated when the tumors were palpable by intravenous (IV) 
administration twice a week, at which time the tumors were measured by digital caliper 
measurements and calculated as length x width x height. The first group was IV injected with 
100 µL saline, this served as the control group. The second group was IV injected with 100 µL 
Res-PdNP-4 (0.25 mg/kg bw) whereas the third group was IV injected with 100 µL free Res (7 
mg/kg bw). An additional control group of normal untreated mice was added to the study, which 
served as controls for the complete blood count (CBC) values. The study was conducted for 31 
days; day 0 was considered the day of randomization and the day of initial treatment.  
Results of the therapeutic study indicated that Res-PdNP-4 has the ability to control the tumor 
volume in comparison to the saline control group and free Res treated group (Figure 38). 
Approximately after one week of treatment (day 10), the tumor size was controlled by Res-
PdNP-4 at 0.04±0.02 cm
3
 while the group treated with saline (0.05±0.02 cm
3
) and free Res 
(0.08±0.06 cm
3
) started to show a slight increase in the tumor size. The tumor size of the first 
and third group (saline and free Res) at two week post injection (day 17) was much greater than 
the previous week greater at 0.06±0.02 cm
3
 and 0.1±0.05 cm
3
, respectively, as compared to the 
143 
 
Res-PdNP-4 treatment in which the tumor size was controlled at 0.04±0.02 cm
3
 as shown in 
Figure 38.  
Four weeks post treatment (day 31), there was a transient increase in the tumor size  at 0.2±0.1 
cm
3
 and 0.3±0.05 cm
3
 for the groups treated with saline and free Res, respectively. The tumor 
size for Res-PdNP-4 treated group was 0.1±0.04 cm
3
, which clearly showed the ability of Res-
PdNP-4 to control the tumor growth. By day 35, only few animals from all the treated groups 
remained alive while many animals were euthanized due to tumor burden during the study. From 
the saline control and free Res groups only 1 out of 5 animals and 3 out of 5 animals from Res-
PdNP-4 remained alive. The body weights were taken twice a week during treatment until the 
end of the study, no significant body weight loss was observed for the Res-PdNP-4 treatment 
compared to the normal healthy control group as shown in Figure 39. The in vivo therapeutic 
efficacy shows that Res-PdNP-4 are highly effective compared to free Res, which was due to the 
high corona of Res on the PdNPs and PdNPs facilitated effectively enhanced delivery of Res 
with high bioavailability, giving an advantage in tumor therapy. A study by Chen et al.
66
 reported 
that Pd nanosheets in vivo accumulate in the liver and spleen from IV administration which was 
Pd nanosheet size and time point post-injection dependent. At 4 days post-injection, the Pd 
nanosheets were cleared by renal excretion while at 30 days post-injection their data revealed 
that 13 nm Pd nanosheets were in the spleen. We believe that the Res-PdNP-4 have a similar 
route of clearance because of the comparable size with the Pd nanosheets.  
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Figure 38: Therapeutic efficacy studies of prostate tumor-bearing SCID male mice treated 
by intravenous injection twice a week with Res-PdNP-4, Res and saline. 
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Figure 39: Average body weight of the SCID male mice during the study. 
Blood parameters within the tumor-bearing saline, free Res and Res-PdNP-4 treatment groups 
were compared with baseline levels from a normal healthy group that had not been 
experimentally manipulated and served as the control for this analysis. The parameters that were 
compared included mean counts for white blood cells (WBC), red blood cells (RBC) as well as 
hemoglobin, lymphocytes, and platelets counts. The analysis revealed that the mean WBC count 
for the Res-PdNP-4 treated group was 2.2±1.1 x 10
3
 WBC/µL, saline treated group was 3.7±2.0 
x 10
3
 WBC/µL and 3.5±1.4 x 10
3
 WBC/µL for free Res treated group. By contrast, the WBC 
count for the normal control group was 1.6±0.5 x 10
3
 WBC/µL. There was no significant 
difference in WBC count among all the treated groups. The mean RBC count, hemoglobin 
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(g/dL), lymphocytes and platelets count, revealed that there was no significant differences among 
treated groups and slightly lower than those of the control group. Moreover, the platelets counts 
for the control group was 657.5±212.3 x 10
3
/µL, while the Res-PdNP-4, saline and free Res 
treated groups was 697.5±174.6 x 10
3
/µL, 900.2±307.1 x 10
3
/µL and 847±217.1 x 10
3
/µL, 
respectively. 
4.12.1 Immunohistochemistry of tumor xenografts 
Tumor growth is directly proportional to sufficient blood vessels present in the tissue responsible 
for the blood supply through sprouting angiogenesis and co-option of existing blood vessels.
67
 
The mean microvessel density (MVD) was measured to evaluate neovascularization within the 
tumor xenografts by CD31 staining; this was quantified by ImageJ Immunohistochemistry (IHC) 
Image Analysis software. The CD31 positively stained vessels in prostate cancer tissue sections 
are shown in Figure 40a-c, respectively. Res-PdNP-4 treatment revealed a substantial decrease in 
number of microvessel density (MVD) at 35±5 vessels per mm
2
 compared to the saline and free 
Res treated groups at 72±3 and 85±5 vessels per mm2, respectively.  
The obtained MVD data are clearly indicative and support the therapeutic efficacy in vivo results 
that Res-PdNP-4 has the ability to control the tumor volume compared to the saline and free Res 
treated group. Analysis of tissue CD31 biomarker showed that the Res-PdNP-4 inhibited 
angiogenesis in tumor tissue. Thus, the results indicated that Res-PdNP-4 was obviously efficient 
for prostate cancer cells, a synergism of antitumor property of Res-derived phenols and 
polyphenols with PdNPs nanocarrier delivery for increased Res-derived phenols and polyphenols 
bioavailability in comparison to the saline control group and free Res treated groups.   
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Figure 40: Immunohistochemical CD31 staining of tumor tissues to evaluate blood vessels. 
Twelve fields from each xenograft were analyzed to determine the average number of 
vessels per field (microvessel density= MVD). N=3; mean±STEM; a) saline control group, 
b) free Res treated group and c) Res-PdNP-4 treated group.  
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CHAPTER 5 
CONCLUSION 
The present research resulted in the development of four types of resveratrol encapsulated 
palladium nanoparticles: Res-PdNP-1, Res-PdNP-2 (increased Res-derived phenols and 
polyphenols corona), Res-PdNP-4 (stabilized with GA) and Res-PdNP-4 (increased Res-derived 
phenols and polyphenols corona stabilized with GA). The production of nanoparticles with a 
higher Res corona (Res-PdNP-2 and Res-PdNP-4) was not accidental after completing extensive 
optimization and research on achieving this synthetic route was challenging. The Res-PdNPs can 
be used for the treatment of prostate cancer through selective and specific target-mediated 
delivery to achieve a high therapeutic benefit without affecting surrounding healthy tissues.  
In the first project of this study, resveratrol served a dual role as a reducing and stabilizing agent 
for the reduction of Pd within the Na2PdCl4 salt to the corresponding palladium nanoparticles. 
The synthesis route to achieve the synthesis of Res-PdNP-1 was successful. Based on the results 
obtained of Res-PdNP-1, the amount of Res-derived phenols and polyphenols loaded onto the 
palladium nanoparticles was less to achieve high therapeutic effect. This prompted further 
investigation, into increasing the Res-derived phenols and polyphenols corona on the PdNPs. 
The protocols that were established to synthesize increased Res-derived phenols and polyphenols 
corona by using more Res in the reaction were successful; this was evident through the 
production of Res-PdNP-2. The in vitro stability data of Res-PdNP-1 and Res-PdNP-2 revealed 
that Res-PdNPs were not stable in serum.  
In the second project of this study, the development of stable Res-PdNPs using gum arabic (GA). 
The introduction of GA provided much needed stability to the Res-PdNPs and the Res-PdNP-3 
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and Res-PdNP-4 were stable in all biological media tested. Moreover, TEM results revealed that 
GA was not limited to the stability of the Res-PdNP-3 but also facilitated the crystallization of 
the produced palladium nanoparticles (Res-PdNP-3 and Res-PdNP-4) and subsequently provided 
a supportive matrix with higher resveratrol-derived phenols and polyphenols loading capacity. 
The 
1
H NMR results demonstrated that oxidized Res, as well as oxidized products (piceatannol, 
3,5-dihydroxybenzoic acid, 3,5-dihydroxybenzaldehyde and para-hydroxybenzaldehyde) of Res 
on the PdNPs. The Res-PdNP-4 was considered the ideal Res-PdNPs for further investigation 
because of their high stability and Res corona in order to improve the bioavailability, 
biodistribution and provide an adjuvant therapy to induce selective and specific prostate tumor-
cell-death. The in vitro cellular results revealed that Res-PdNP-4 were selective to the laminin 
receptors overexpressed in prostate cancer cells. This was established through cellular 
internalization results which confirmed Res-PdNP-4 cellular internalization is mediated through 
an endocytic pathway. The cellular viability results of Res-PdNP-4 nanoparticles exhibited 
comparable anticancer efficacy against prostate cancer (PC-3) cells as chemotherapy drugs 
(cisplatin and etoposide), while cisplatin and etoposide treatments were highly toxic to normal 
HAEC cells due to the toxicity profile. The Res-PdNP-4 is an excellent candidate to be used for 
treatment of prostate cancer because they presented no toxicity against HAEC cells.   
In the third project of this study, the therapeutic efficacy results showed that Res-PdNP-4 
nanoparticles have significant therapeutic effect and are able to control the tumor size in 
comparison to the control and free resveratrol treated groups. It is remarkable to conclude from 
these results that tumor selective affinity of Res-PdNP-4 provides an additional armamentarium 
for therapy through antitumor property of high Res corona and adjuvant therapeutic benefits 
through PdNPs for the destruction of tumor without affecting surround tissues.  
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FUTURE WORK 
The promising results of the experiments that were performed in the present study to develop 
Res-PdNPs for prostate cancer treatment and imaging requires further research work in order to 
transfer them from experimental work to clinical trials. 
Further investigation of the oxidized Res products (Res-derived phenols and polyphenols) on the 
PdNPs are required to fully understand the identity of the encapsulated compounds. The in vivo 
evaluation results of Res-PdNP-4 in SCID mice showed that these nanoparticles dose response 
was good, although further studies are required to determine a better dose to see increased 
efficacy. The dose administrated was well tolerated by the animals, as no animal health problems 
or discomfort was observed as evidenced by body weight/eating habits of animals. This study 
was performed through intravenous (IV) administration of the Res-PdNP-4, intraperitoneal (IP) 
delivery and direct injection into the tumor may show better response as has been the case with 
many different types of nanoparticles. 
The exploration of using an external beam such as near-infrared to excite PdNPs through the use 
of different laser techniques for photodynamic therapy. More animals studies by using larger 
animals such as dogs needs to be performed to confirm the efficacy of these nanoparticles to cure 
prostate cancer because the organs of larger animals such as dogs nearly similar to the organs of 
humans and therefore the results will be more accurate and similar to what supposed to be in 
humans. The results of the future studies determine transferring Res-PdNP-4 from experimental 
trial to clinical trial. The Res-PdNP-4 can be evaluated to treat other cancers such as breast and 
lung cancer in the future.  
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APPENDIX 
A - Cellular viability of Res-PdNP-4 against prostate cancer (PC-3) cells  
 
 
Figure 41: Cell viability of prostate cancer (PC-3) after a) 24 h and b) 48 h post incubation 
with Res-PdNP-4 and controls (free Res, GA, GA-PdNPs, cisplatin and etoposide), n=4; 
results reported as mean±SEM.  
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B - Cellular viability of Res-PdNP-4 against human aortic endothelial cells (HAEC) 
 
Figure 42: Cell viability of human aortic endothelial cells (HAEC) after a) 24 h and b) 48 h 
post incubation with Res-PdNP-4 and controls (cisplatin and etoposide). At high Res-
PdNP-4 concentration no toxicity was observed (green arrow), n=4; results reported as 
mean±SEM. 
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